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INTRODUCTION 
ADVANTAGES OF NEUROTOXIN INDUCED LESIONS 
The physical lesioning techniques used to alter the 
structure of the brain such as radio frequency generated 
heat, cutting, freezing and suctioning were rather unse-
lective in their effects. These aforementioned techniques 
destroyed all neuronal cell bodies, dendritic arboriza-
tions, synaptic terminals and axonal projections which were 
physically located at the site of the lesion. Thus, when 
the physical techniques were utilized, any post-lesion 
changes in behavior could not be ascribed to the destruc-
tion of a single brain structure or a single neuronal type 
as characterized by its transmitter. 
Recently, a method of lesioning the brain by means of 
neurotoxins came into vogue as neurotoxins with allegedly 
very specific destructive effects were developed. For 
example, a neurotoxin useful for the study of dopaminergic 
function should only destroy dopaminergic cells. It was 
expected that the use of such a neurotoxin would result in 
readily interpretable experimental findings and that the 
functional significance of the destroyed cells could be un-
equivocally deduced (Ungerstedt, 1973). 
1 
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6-Hydroxydopamine (6-0HDA) and 5,6-dihydroxytrypta-
mine (5,6-0HT) were two of the earliest agents claimed to 
have specific neurotoxic actions on catecholamine (Unger-
stedt, 197lb) and indoleamine (Baumgarten et al., 1971) 
neurons, respectively. The research reported in these 
pages examines the specificity of action and certain per-
tinent problems concerning these two neurotoxic agents. 
METHODS OF ADMINISTRATION OF NEUROTOXIC AGENTS 
Neurotoxic agents may be administered peripherally 
or into the brain and its ventricles, and their desired 
effects may be upon either the peripheral nervous system, 
the central nervous system (CNS) or both. In the case of 
6-hydroxydopamine (6-0HDA), peripheral administration re-
sults only in the destruction of the peripheral sympathetic 
nerves since the compound does not pass the blood brain 
barrier (Stone et al., 1962; Laverty et al., 1965; Clark et 
al., 1971). However, this peripheral selectivity is depen-
dent upon the complete development of the blood brain 
barrier since brain norepinephrine (NE) can be depleted by 
the systemic administration of 6-0HDA to neonatal rats 
(Clark et al., 1972). Uretsky and Iversen (1969) demon-
strated the central action of 6-0HDA after its intraven-
tricular administration to adult rats. 
3 
In contrast, another neurotoxic agent, 6-hydroxydopa 
{6-0HDQPA} is able to penetrate the blood brain barrier 
and can induce destructive inf·luences in the periphery as 
well as the CNS following its systemic administration 
{Sachs and Jonsson, 1972; Jacobowitz and Kostrzewa, 1971). 
However, selective lesions of the CNS, without involvement 
of the periphery, were achieved by direct application of 
6-0HDOPA to the CNS {Kmieciak-Kolada, et al., 1974). 
Pharmacological manipulations can also alter the 
actions of a neurotoxic agent. Jonsson and Sachs {1973) 
demonstrated that monamine oxidase inhibition enhances the 
neurotoxic action of 6-0HDOPA. Similarly, Breese and 
Traylor {1970) demonstrated that monamine oxidase inhibi-
tion markedly enhanced the dopamine depleting properties of 
intracisternally administered 6-0HDA. In contrast, the 
administration of desmethylimipramine almost completely 
prevented the degeneration of noradrenergic terminals by 
6-0HDOPA {Jonsson and Sachs, 1973). 
The route of administration can drastically affect the 
selectivity of 5,6-dihydroxytryptamine (5,6-0HT); systemic 
administration can result in a sympathectomy similar to that 
induced by 6-0HDA Baumgarten et al., 1972d). However, cen-
tral administration results in specific lesions of indola-
minergic neurons in preference to catecholaminergic neurons 
{Baumgarten et al., 1971). 
4 
In summary, 6-0HDA, as a neurotoxin, has been applied 
centrally either intraventricularly (Barnes et al., 1973a, 
b), intracisternally (Breese et al., 1970) or intracere-
brally (Ungerstedt, 1973) • The resultant destructive 
effects were upon the catecholaminergic terminals, axons 
and soma. 5,6-0HT, on the other hand, has been applied pri-
marily via the intraventricular route (Baumgarten et al., 
1971, 1972c; Barnes et al., 1973c; Da Prada et al., 1972; 
costa et al., 1972). 
METHODS OF ASSESSING THE SELECTIVITY OF NEUROTOXIN INDUCED 
LESIONS IN THE CNS 
It is important to emphasize the distinction between 
the terms "specific" and "selective" since they are fre-
quently used to describe neurotoxin actions. A neurotoxin 
is said to be specific if it possesses a single neurotoxic 
action; that is, at all effective doses the neurotoxin in 
question would be toxic to only one type of cell. In con-
trast a neurotoxin is said to be selective when it exerts a 
toxic effect upon one type of neuron at one dose, but at 
another dose the neurotoxin will also exhibit toxic effects 
upon several other neurons; this toxicity on several types 
of neurons may exhibit a dose response relationship. 
5 
NEUROCHEMICAL APPROACHES 
In order to assess the specificity of neurotoxin 
action one would have to investigate the effects of the 
neurotoxin on many neurotransmitter systems. For example, 
with the neurochemical approach one may assess the destruc-
tion induced by a neurotoxin by measuring the amount of the 
neurotransmitter that would normally be present in the af-
fected cells or nerve terminals. Other neurochemical ap-
proaches involve the measuring of alterations in the activ-
ity of biosynthetic enzymes or in the catabolism of exogen-
ously administered neurotransmitter, or in membrane trans-
port mechanisms. 
In the case of the cholinergic system one may deter-
mine as neurochemical parameters the levels of ACh, the 
activity of acetylcholinesterase {AChE) , uptake of choline, 
or the activity of choline acetyl transferase {ChAc) • De-
creases in any of the parameters mentioned above may be 
indicative of destructive influences on central cholinergic 
neurons. 
Similarly, if the serotonergic system was destroyed 
one might expect to find decreases in the brain content of 
5-HT, uptake of 5-HT or in the specific activity of trypto-
phan hydroxylase. Obviously the functional biochemical 
6 
characteristics of the specific neurotransmitter system 
involved would define the neurochemical approach to be 
taken. 
The following findings with 6-0HDA should give in-
sight as to the types of neurochemical changes that could 
be expected with a specific neurotoxin for catecholaminer-
gic neurons. Sufficient neurochemical evidence exists in 
the case of 6-0HDA to indicate that destruction of central 
catecholaminergic systems occurred in rats after the cen-
tral administration of the compound. For example, it was 
shown that the administration of 6-0HDA lowers the brain 
content of NE (Bloom et al., 1969; Uretsky and Iversen, 
1969; Breese and Traylor, 1970; Scotti et al., 1971) and 
dopamine (Bloom et al., 1969; Breese and Traylor, 1970; 
Barnes et al., 1973b). As the major mechanism for the 
termination of central and peripheral catecho~amine neuro-
transmission is thought to be a rapid presynaptic uptake of 
released catecholamines (Glowinski and Iversen, 1966) , it 
may be expected that the destruction of catecholamine nerve 
terminals should impair this uptake. In fact, the uptake 
of NE was markedly diminished in rat brain following 6-0HDA 
treatment (Uretsky and Iversen, 1969; Uretsky et al., 1971). 
Similar effects were observed in the periphery (Jonsson and 
Sachs, 1970; Thonen, 1971). 
Intraventricular administration of 6-0HDA to rats 
7 
significantly reduced the uptake of tritiated NE in hypo-
thalamus and striatum but not in the pons-medulla region 
(Uretsky et al., 1971). These regional differences in up-
take of tritiated norepinephrine after 6-0HDA are postu-
lated to indicate a greater susceptibility to destruction 
of noradrenergic terminals than of noradrenergic cell 
bodies by the neurotoxin (Uretsky et al., 1971). 
Additionally, as a result of neurotoxin action there 
may be changes in the activity of biosynthetic enzymes. In 
fact, following the 6-0HDA treatment the activity of ty-
rosine hydroxylase was markedly diminished (Breese and 
Traylor, 1970). 
The catabolism of neurotransmitter may also be af-
fected by a neurotoxin, as following 6-0HDA pretreatment, 
increased amounts of normetanephrine were observed after 
exogenously administered a3-norepinephrine (Uretsky and 
Iversen, 1971; Breese and Traylor, 1970). Moreover, 6-0HDA 
treatment increased the formation of non-deaminated, ortho-
methylated metabolites by catechol o-methyl-transferase 
(COMT) (Breese and Traylor, 1970). The increase in the 
amount of o-methylated metabolites mimicked a loss of MAO 
activity. However, 6-0HDA did not alter MAO activity 
(Breese and Traylor, 1970). Thus the increase in COMT 
metabolites most probably resulted from the loss of the 
presynaptic uptake of NE which reduced the availability of 
8 
NE for deamination by MAO {Breese and Traylor, 1970). 
Neurotoxins may also alter neurotransmitter turnover. 
6-0HDA treatment decreased the turnover of NE {Bloom et al., 
1969; Uretsky et al., 1971). 
Analogous findings with regard to the changes in the 
serotonergic system were observed following 5,6-0HT treat-
ment. Long lasting depletions of serotonin have been re-
ported following intraventricular injections of 5,6-0HT 
(Baumgarten et al., 1971; Baumgarten et al., 1972b; Bjork-
lund et al., 1974; Barnes et al., ~973c; Longo et al., 
1974). The uptake of 5-HT was· reduced by 5,6-0HT pretreat-
ment (Daly et al., 1973). Furthermore, the activity of the 
biosynthetic enzyme tryptophan hydroxylase was also dimin-
ished following 5,6-0HT (Victor et al., 1973; Levenberg 
and Victor, 1974). Thus, a convincing case may be made 
with a neurochemical approach for specific destructive ef-
fects of 6-0HDA and 5,6-0HT on the noradrenergic and sero-
tonergic systems respectively. 
However, in order to classify a neurotoxin as having 
a specific action it must be demonstrated that the neuro-
toxin only affects a single neurotransmitter system. In 
the case of 6-0HDA, it was apparent that the compound af-
fected both noradrenergic as well as dopaminergic nerve 
terminals (Breese and Traylor, 1970; Bell et al., 1970; 
Uretsky and Iversen, 1970). In addition, 6-0HDA may affect 
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rat brain 5-HT content (Bloom et al., 1969). On the other 
hand 6-0HDA had no effect on the brain content of GABA or 
several other amino acids postulated to have neurotrans-
mitter roles (Uretsky and Iversen, 1970; Jacks et al., 
1972). 6-0HDA was reported to decrease striatal acetylcho-
linesterase levels (Kim, 1973) and either to increase (Kim, 
1973) or to have no effect (Consolo et al., 1974; Jacks et 
al., 1972) on striatal ACh. Thus, 6-0HDA may be able to 
affect several neurotransmitter systems. Similarly to 
6-0HDA, the neurotoxin 5,6-0HT was found to have a selec-
tive rather than a specific action on brain neurotransmit-
ter systems. Brain NE and DA contents were lowered by 
sufficiently high doses of 5,6-0HT (Bjorklund et al., 1974; 
Baumgarten et al., 1972b). 
Thus, it is probably more correct to speak of neuro-
toxin selectivity rather than specificity. That is, until 
proven otherwise, one should assume that a neurotoxin does 
not affect a single neurotransmitter system (i.e. is not 
specific); however, the neurotoxin may be more effective 
with respect to one neurotransmitter system as compared to 
another (i.e.-it'may be selective). The degree of neuro-
toxin selectivity would be dependent primarily upon the 
degree of separation that would exist between the effect on 
one system versus another. These preceding statements are 
in essence a restatement of a basic pharmacological con-
10 
cept; that drugs affect many biological systems and gen-
erally are selective rather than specific in their actions. 
HISTOLOGICAL APPROACHES 
Histological and histochemical examination of the 
brain and specific pathways, the neurotransmitter composi-
tion of which is known, is an extremely valuable tool in 
determining the extent of neurotoxin induced neuronal dam-
age. A histochemical fluorescence technique is available 
to localize the catecholamines and indoleamines within the 
brain (Dahlstrom and Fuxe, 1964). This technique has been 
methodically applied to illustrate the cellular sequelae 
of the central administration of either 6-0HDA or 5,6-0HT. 
The histological changes induced by 6-0HDA were 
similar in the periphery and in the CNS. In the periphery, 
6-0HDA produces visible evidence of adrenergic nerve ter-
minal degeneration (Tranzer and Thoenen, 1968). Centrally 
administered 6-0HDA also produces visual signs of neuro-
toxicity to NE and DA terminals and DA cell bodies (Unger-
stedt, 197lb; Bloom et al., 1969). Similarly, microscopic 
and histochemical studies of neurons after 5,6-0HT have 
yielded visual evidence of destruction of noradrenergic 
terminals in the periphery (Baumgarten et al., 1972d) while 
in the CNS both 5-HT terminals (Baumgarten and Lachenmayer, 
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1972; Baumgarten et al., 1972c) and axons (Baumgarten, 
l972a) show visible evidence of destruction after 5,6-0HT. 
Histological and histochemical analysis allows for a 
simultaneous evaluation of neurotoxin induced destruction 
of the target as well as non-target structures. Such an 
examination would be difficult if not impossible with the 
neurochemical approach. However, the approaches are com-
plementary and taken together provide the strongest evi-
dence for specificity and/or selectivity of the neurotoxin 
action. 
BEHAVIORAL APPROACHES 
Present day neuroscience demands the determination of 
the relevance of experimentally induced neurochemical and 
histological changes, particularly by means of investiga-
tions of behavioral correlates of the induced neurochemical 
or histological changes. It became apparent from such in-
vestigations that many behaviors have a multitransmitter 
basis. Thus, the behavioral effect of a neurotoxin cannot 
be readily ascribed to its action on a specific neurotrans-
mitter system, till its action on other neurotransmitter 
systems can be excluded. 
The biogenic amines have been implicated as modula-
tors of many behaviors, and the behavioral correlates of 
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the action of the neurotoxins 6-0HDA and 5,6-0HT have been 
extensively investigated. In most cases the effects of 
these neurotoxins have supported the concept of a modula-
tory role of the biogenic amines in several behaviors; 
examples of the behavioral sequelae of the actions of 6-
0HDA and 5,6-0HT are adduced below. It will become ap-
parent on the basis of these examples that the question of 
selectivity of action of either 6-0HDA or 5,6-0HT has not 
been thoroughly investigated by means of the behavioral 
approach; in most cases, there are no data sufficient to 
correlate a specific neurochemical effect with the behav-
ioral action. 
One pertinent example concerns the avoidance response. 
The catecholamines have been implicated in avoidance re-
sponding for many years as the neuroleptics were found to 
be capable of inhibiting this response (Hanson et al., 
1966) • A cholinergic component was also implicated since 
anticholinergic agents reversed the block of avoidance in-
duced by dopamine blocking agents (Hanson and Stone, 1964; 
Fibiger and Phillips, 1974). In addition, a modulatory 
role for serotonin has been suggested from genetic studies 
(Oliverio et al., 1974). Yet, 6-0HDA studies suggest that 
NE may not be needed for avoidance. Indeed, stereotaxic 
injections of 6-0HDA into the tegmental area containing the 
NE ascending fiber tracts did not impair the acquisition of 
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avoidance (Cooper et al., 1974). However, stereotaxic 6-
0HDA injections which involved the ascending dopaminergic 
fiber bundles, or terminals in the caudate-putamen, result-
ed in a marked inhibition of acquisition (Cooper et al., 
1974). Similar results were observed by Fibiger et al. 
(1974) who reported an impairment in the acquisition of one 
way active avoidance in rats pretreated with 6-0HDA. 
A similar situation occurs with regard to the "reward 
system". While these data may indicate that 6-0HDA exerts 
a specific dopaminergic rather than a noradrenergic effect 
on avoidance, the literature dealing with this matter is 
controversial, and the question is not settled. Previous 
work by Stein et al. (1968) employing the intracranial self 
stimulation technique resulted in a noradrenergic theory of 
reward; that is, noradrenaline was proposed to be the neu-
rotransmitter required for self stimulation. Recently, 
6-0HDA has been used to support this concept (Stein, 1971) • 
After 6-0HDA both the brain norepinephrine content and the 
self stimulation rate were decreased (Stein, 1971). How-
ever, other investigators rejected a modulatory role of 
norepinephrine in self stimulation; since after 6-0HDA, 
they were able to initiate normal rates of self stimulation 
in spite of significant reductions in brain NE (Antelman 
et al., 1972). Furthermore, a facilitatory modulatory role 
for DA was proposed, when the intraventricular administra-
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tion of haloperidol, a dopamine receptor blocker, signi-
ficantly suppressed the rate of self stimulation (Lippa et 
al., 1972). Moreover, the identification of other modula-
tory neurotransmitters complicates the analysis of this 
behavior. For example, an inhibitory modulatory role for 
the serotonergic syst·em has also been suggested to be an 
important regulator of intracranial self stimulation, i.e. 
reward behavior (Peschel and Ninteman, 1971). 
The biogenic amines have also been implicated in 
nocioception. A serotonergic mechanism has been implicated 
in morphine analgesia (Tenen, 1968). It was found, using 
the flinch-jump method of Evans (1961) that the tryptophan 
hydroxylase inhibitor, parachlorophenylalanine (PCPA; Koe 
and Weissman, 1966) inhibited the analgesic effect of mor-
phine. These data were supported by the fact that PCPA or 
a lesion of the median forebrain bundle which depleted 
brain 5-HT, increased the animal sensitivity to pain, with-
out also increasing the animals' generalized responsiveness 
to a puff of air (Harvey and Yunger, 1973). However, these 
later investigators could not alter morphine analgesia by 
either method and concluded that morphine analgesia is not 
modulated by 5-HT (Harvey et al., 1974). In contrast, 
lesions of the midbrain raphe nuclei did not affect pain 
sensitivity but abolished the analgesic effect of morphine 
(Pepeu et al., 1974a). The lesions of the midbrain raphe 
15 
in addition to depleting brain 5-HT also decreased ACh 
content in the telendiencephalic portion of rat brain. The 
picture is further complicated by the fact that PCPA also 
depletes brain norepinephrine content (Miller et al., 
1970), and MFB lesions deplete dopamine as well as NE con-
tent (Harvey et al., 1974). Thus, we are still at a con-
troversial stage in the understanding of the role of neuro-
transmitters in pain sensitivity and drug induced anal-
gesia. Selective neurotoxins may aid our understanding in 
this area. 
Still another example illustrating the difficulty in 
relating a behavior to a specific neurotransmitter concerns 
aggression. The serotonergic system has been implicated in 
aggressive behavior but not without confounding influences 
from other neurotransmitter systems. Muricidal rats appear 
to have an alteration of serotonergic activity (Di Chiara 
et al., 1971) but an interaction with ACh can not be ex-
cluded in this behavior because o·f its induction by chronic 
dosing of pilocarpine (Haubrich and Reid, 1972; Vogel and 
Leaf, 1972). Similarly, in the case of isolation induced 
aggression in the mouse, it has been suggested that the de-
creased turnover in serotonergic as well as catecholaminer-
gic neurons may be necessary (Valzelli, 1974). Thus, 
assessment of neurotoxin selectivity with this procedure 
would not be meaningful without a neurochemical analysis of 
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all the neurotransmitter systems involved. 
The sexual behavior of male rats was found to be 
modulated by several biogenic amines. The sexual behavior 
of male rats was inhibited by activity of the serotonergic 
system (Tagliamonte et al., 1969). However, as PCPA has no 
effect on the sexual activity of cats, the general appli-
cability of a serotonergic concept has been questioned 
(Zitrin et al., 1970). Furthermore, the sexual behavior of 
the rat may also be modulated by a dopaminergic facilita-
tory mechanism (Gessa and Tagliamonte, 1974). The use of 
the neurotoxin 5,6-0HT supports the serotonergic involve-
ment in sexual behavior since after its administration a 
hypersexual response is induced (Da Prada et al., 1972). 
On the other hand, the failure to decrease the facilitatory 
effect of 5,6-0HT by means of 6-0HDA suggests that some ad-
ditional clarification regarding the postulated facilita-
tory role of dopamine is indicated (Da Prada et al., 1972). 
Locomotor activity has also been suggested to have a 
multineurotransmitter basis. There is much evidence to 
suggest that the central catecholaminergic system provides 
a facilitatory modulation of locomotion. Evidence for a 
relationship between central catecholamines and the loco-
motion was provided by the early work with reserpine. Re-
serpine treatment depressed locomotion and decreased the 
brain content of norepinephrine of rats (Holzbauer and 
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vogt, 1956). However, reserpine also depleted serotonin 
and the remarkable behavioral depression which ensued was 
ascribed to a central re~ease of serotonin (Brodie et al., 
1959). The demonstration that a good correlation existed 
between reserpine induced locomotor depression and catecho-
lamine depletion tended to refute the serotonergic hypoth-
esis (Carlsson, 1961; Matsuoka et al., 1964). Additional 
support for a direct involvement of catecholamines was ob-
tained by the discovery that L-DOPA effectively reversed 
the reserpine depression while 5-HTP did not (Blaschke and 
Chrusciel, 1960; Carlsson et al., 1957). 
The role of the catecholamines in locomotor behavior 
became more firmly established with the discovery of alpha-
methylparatyrosine <~-mpt), a compound which inhibits 
tyrosine hydroxylase, and selectively depletes brain cate-
cholamines without altering brain 5-HT levels (Weissman, 
1965) • The locomotor depression induced by alpha-methyl-
paratyrosine was consistent with the locomotor stimulation 
induced by amphetamine, primarily a releaser of catechola-
mines (Moore et al., 1970). Furthermore, the stimulant 
actions of amphetamine were reported to be blocked by 
alpha-methylparatyrosine (Weissman, 1966; Rech, 1970); this 
fact further supported the role of catecholamines in loco-
motor behavior. L-DOPA, which does not require the action 
of tyrosine hydroxylase to form catecholamines, was able to 
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reverse the ~-mpt induced depression of locomotion (Moore 
and Rech, 1967). Altogether, these data suggest a strong 
facilitatory effect of catecholamines on the locomotor be-
havior of the rodent. 
The results obtained with a potent dopamine-p;' -
hydroxylase inhibitor, FLA-63, which blocked the synthesis 
of norepinephrine from dopamine suggested an involvement of 
NE in locomotion, as FLA-63 produced a reduction in loco-
motor activity at doses which depressed the brain content 
of NE (Svensson and Waldeck, 1969). Furthermore, the loco-
motor stimulant effect of L-DOPA was antagonized by FLA-63 
(Stromberg and Svensson, 1971). Finally, the FLA-63 in-
duced depression of locomotor activity was reversed by a 
monamine oxidase inhibitor (Svensson, 1970). 
Studies with the centrally acting ~-receptor 
agonist, clonidine and the ~-receptor antagonist, phenoxy-
benzamine also implicated norepinephine, a long recognized 
o(-receptor agonist, as a facilitatory modulator of locomo-
tion. Spinal cats were stimulated into active coordinated 
locomotor movements by clonidine (Forssberg and Grillner, 
1973). A central blocking activity was demonstrated for 
phenoxybenzamine in spinal cats (Anden et al., 1967). Fi-
nally, clonidine enhances the locomotor stimulation induced 
by apomorphine following reserpine (Anden and Strombom, 
1974) • This stimulation of locomotion by clonidine was 
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antagonized by phenoxybenzamine (Anden and Strombom, 1974) • 
In addition, the cholinergic system may also con-
tribute an inhibitory modulation of locomotion. The cho-
linergic modulation may be indirect through an influence 
on the catecholaminergic system. Indeed, the locomotor 
stimulation induced by muscarinic blocking drugs is de-
pendent upon an intact catecholaminergic system (Thornburg 
and Moore, 1973a, b). 
The exact nature of the modulatory role of serotonin 
in locomotor behavior is still controversial. For example, 
a facilitatory modulation of locomotion by serotonin has 
been postulated to be independent of the catecholamines 
(Modigh, 1974). In contrast, a serotonergic inhibition of 
catecholamine induced stimulation of locomotion has also 
been postulated (Mabry and Campbell, 1973). Further re-
search will be needed to clarify the role of serotonin in 
this behavior •. 
6-Hydroxydopamine treatment has been shown to induce 
a transient decrease in locomotor activity (Breese and 
Traylor, 1970; Scotti de Carolis et al., 1971). Similarly, 
5,6-0HT has also been shown to depress locomotor activity 
of rodents (Barnes et al., 1973c; Longo et al., 1974). 
Thus, the neurotoxins' effects on locomotor behavior sup-
port the concept of a modulatory role of the bioamines in 
this behavior. 
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In conclusion, it is apparent that 6-0HDA and 5,6-0HT 
have dramatic influences on behavior. Moreover, because of 
the multineurotransmitter basis of the behaviors studied, 
the behavioral effects of 6-0HDA or 5,6-0HT treatments can-
not stand alone as an argument for neurotoxin specificity 
or selectivity. 
PHARMACOLOGICAL APPROACHES 
The proof of neurotoxin selectivity by means of the 
pharmacological approach primarily depends upon the demon-
stration of selective changes in the responsiveness of the 
organism to drugs i.e. changes in the drug-receptor inter-
action. It may be expected that the pharmacological changes 
induced by a neurotoxin induced lesion of the brain should 
resemble those induced by physical induced lesions. These 
changes frequently take the form of a supersensitivity, al~ 
though a subsensit.ivity may also develop. Thus, one may 
use the presence of either supersensitivity or subsensitiv-
ity to a specific agonist as a marker of the damage to a 
biological system which is normally affected by that 
agonist. This present investigation in part, explored the 
extent that supersensitivity or subsensitivity would re-
veal the nature of the neurotoxicity induced by 6-0HDA or 
5,6-0HT. 
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At the time of this investigation very little was 
known about the nature of supersensitivity in the nervous 
system. Most of our knowledge about supersensitivity was 
derived from investigations of the denervation phenomena 
at the periphery. Therefore, supersensitivity phenomena 
at the peripheral level will be described to characterize 
their nature and to provide the implications for the 
studies of the selectivity of neurotoxin action in the CNS. 
THE TERMINOLOGY OF SUPERSENSITIVITY PHENOMENA 
Lesions of the nervous system can induce changes in 
the innervated structure's responsiveness to agonists. The 
change usually takes the form of an enhanced response. The 
term "denervation supersensitivity" was used to describe 
this phenomenon. Cannon and Rosenbluth (1949) indicated 
that the phenomenon was recognized as early as 1880 by 
Claude Bernard. 
The phenomenon of denervation supersensitivity is 
demonstrable when a denervated tissue becomes more respon-
sive than normal to its physiological neurotransmitter; 
supersensitivity should also result in an increased response 
of the tissue to agonist agents which mimic the action of 
the neurotransmitter. 
Interestingly, it has recently been demonstrated that 
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denervation per ·se was not a prerequisite for the develop-
ment of supersensitivity. Basically, it was discovered 
that a reduction in either the prejunctional content of the 
physiological neurotransmitter or in the rate of the pre-
junctional neuronal impulses was sufficient to induce 
supersensitivity. This supersensit.ivity which did not re-
quire denervation was termed "disuse supersensitivity". 
As a result of numerous investigations, several types 
of supersensitivity have been described. Terms such as 
"prejunctiona;t.", "postjunctional", "decentralization", 
"deviation", "denervation", "disuse", "presynaptic", "post-
synaptic", "cocainelike" and "nondeviation" have been used 
to describe these varied forms of supersensitivity. The 
aforementioned terms resulted primarily from investigations 
of supersensitivity in the periphery. It is probable that 
the list may become even more extensive as more knowledge 
about the nature of supersensitivity in the central nervous 
system is obtained. 
SUPE'RSENS:I'TIVI'TY' OF NICOTINIC RECEPTORS 
Supersensitivity is a complex subject as there is no 
universal mechanism to account for the development of 
supersensitivity even within one class of receptor. For 
example, vari.ous structures which contain nicotinic choli-
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nergic receptors display different responses towards dener-
vation. 
Striated muscle contains a nicotinic cholinergic 
receptor and exhibits supersensitivity to acetylcholine 
following denervation. The supersensitivity of denervated 
striated muscle is not specific to acetylcholine. The 
denervated skeletal muscle also exhibits supersensitive re-
sponses to caffeine, potassium and epinephrine as well as 
acetylcholine (Cannon and Rosenbluth, 1949). In contrast 
a different response is observed following denervation of 
a sympathetic ganglion which also contains a nicotinic 
cholinergic receptor. Preganglionectomy of the sympathetic 
ganglion innervating the cat nictitating membrane apparent-
ly results in a subsensitivity of the nicotinic choliner-
gic receptor within that ganglion but strangely a supersen-
sitivity of the muscarinic receptor (Dun et al., 1976) as 
well as the nictitating membrane (Sharpless, 1975). 
SUPERSENS:ITIVITY OF ADRENERGICALLY INNERVATED SMOOTH MUSCLE 
The phenomenon of supersensitivity of smooth muscle 
and its catecholamine receptors appears to be even more 
complex than that of the nicotine receptors in striated 
muscle and the ganglion. Many of the terms used to de-
scribe supersensitivity phenomena are a direct result of 
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research on supersensitivity in smooth muscle. In contrast 
to the somatic nervous system, the denervation supersensi-
ti vi ty which occurs in adrenergically inne.rvated smooth 
muscle of the autonomic nervous system may be pre.junctional 
as well as postjunctional (Trandelenburg, 1966). The terms 
"pre.junctional and postjunctional supersensitivity" refer 
to a mechanism involving the prejunctional neuronal and 
postjunctional smooth muscle side of the neuromyal junc-
tion, respectively. The presence of both types of super-
sensitivity in smooth muscle occurs only in the case of a 
postganglionectomy, while in the case of a preganglionec-
tomy only the postjunctional type occurs (Trandelenburg, 
1966). 
PREJUNCTIONAL TYPE 
The prejunctional type of supersens.itivity occurs 
soon after denervation and appears to be rather specific to 
norepinephrine. Moreover, as a rapid reuptake mechanism 
exists in the adrenergic nerve terminals and functions as 
the major mechanism for the termination of action of synap-
tically released norepinephrine (Glowinski and Iversen, 
1966) ~ any impairment of this reuptake mechanism would al-
low the synaptically released or exogenous NE to interact 
with the postsynaptic receptor for a prolonged period of 
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time. The net result of impaired reuptake would be to 
enhance the agonist action of a fixed amount of NE and to 
reduce the effective agonist concentration of exogenous NE. 
Thus, the loss of a presynaptic uptake process would result 
in a supersensitive response. Thus, the mechanism of pre-
junctional supersensitivity is thought to be due to the 
loss of the reuptake mechanism for liberated catecholamines 
by the degenerating nerve terminal. The term "cocaine-
like supersensitivity" has been used as a synonym for the 
prejunctional type of supersensitivity as cocaine will 
block the uptake of NE by the catecholaminergic nerve ter-
minals (Trandelenburg, 1966). 
POSTJUNCTIONAL TYPE 
The postjunctional type of supersensitivity in 
adrenergically innervated smooth muscle develops slowly and 
is not as specific as the prejunctional type. The smooth 
muscle develops a supersensitive response to acetylcholine, 
potassium ion and to norepinephrine. 
Another term applied to the postjunctional type of 
supersensitivity is "decentralization type". It is in 
reference to decentralization that the term "disuse super-
sensitivity" developed. The concept of disuse was employed 
in pharmacological investigations in which reserpine was 
26 
utilized to deplete the neuron of norepinephrine and to 
induce a state of diminished rather than totally absent 
neuronal function. It was apparent that the type of super-
sensitivity which developed after reserpine, disuse, de-
centralization, or other procedures which diminished the 
flow of neuronal impluses to the adrenoceptive neuroeffect-
or, mimicked that of the postjunctional type as it exhibit-
ed a long latency and a lack of specificity (Westfall, 
1970) • 
DENERVATION SUBSENSITIVITY 
Besides the development of supersensitivity, a sub-
sensitivity to pharmacological agents may also develop. 
Subsensitivity may develop as a change in the agonist re-
ceptor site following extended periods of activation. For 
exarnple,the number of beta adrenergic receptors in frog 
erythrocytes was markedly reduced following a 24 hour ex-
posure to isoproterenol or norepinephrine (Mukherjee et 
al., 1975). Moreover, denervation subsensitivity to in-
direct acting agonists may occur as the latter depend for 
their action upon both an intact nerve terminal and normal 
supplies of releasable neurotransmitter (Flechenstein and 
Burn, 1953) • 
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MECHANISMS OF. SUPERSENSITIVITY DEVELOPMENT 'IN THE PERIPHERY 
Varied mechanisms have been suggested for the devel-
opment of supersensitivity in the periphery. One mechanism 
suggested for the induction of supersensitivity in striated 
muscle was the loss of a trophic factor from the nerve. 
This concept received less emphasis in recent times since 
it was demonstrated that exercising a denervated muscle 
with either electrical stimulation (Lome and Rosenthal, 
1972} or via acetylcholine (Drachman and Witzke, 1972} was 
sufficient to prevent the development of supersensitivity. 
Any trophic influence therefore, must reside within the 
muscle itself and may not be a result of a trophic factor 
released from the nerve terminal. The mechanism of this 
supersensitivity appears to be a proliferation of cholino-
ceptive sites outside of the junctional area (Axelsson and 
Thesleff, 1959}. 
In sympathetically innervated smooth muscle the mech-
anism for the development of supersensitivity of the pre-
junctional type has been shown to be due to the loss of the 
catecholamine reuptake mechanism of the nerve terminal 
(Trandelenburg, 1966}. In contrast, evidence is still be-
ing accumulated to characterize the mechanism for the de-
velopment of supersensitivity of the postjunctional type. 
Fleming et al. (1975} demonstrated a partial depolariza-
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tion, on the order of lOmv., in smooth muscle that exhibit-
ed supersensitivity of the postjunctional type. Further-
more, since no changes were observed in the junctional po-
tentials, it was concluded that there were no changes in 
the postjunctional receptors (Fleming et al., 1975). More-
over, acute depolarization of this tissue results in an 
acutely developing supersensitivity similar to that observ-
ed after decentralization (Fleming et al., 1975). Thus, 
depolarization may play an important role in the postjunc-
tional supersensitivity of sympathetically innervated 
smooth muscle. In addition, the postsynaptic type of 
supersensitive response of smooth muscle to potassium, 
acetylcholine and calcium are dependent upon the presence 
of calcium ion in the external tissue fluid (Carrier, 
1975). In contrast, the supersensitive response of the 
same tissue to catecholamines was independent of external 
calcium concentration (Carrier, 1975). Morphologically, 
an increase in the number of nexial contacts was observed 
after postganglionic denervation of the vas deferens (West-
fall et al., 1975). It was also suggested that an increase 
in ATP parallels or precedes the development of postsynap-
tic supersensitivity in denervated tissues (Westfall et 
al., 19 75) • 
A novel mechanism was recently suggested to explain 
the hydrocortisone induced supersensitivity of the nicti-
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tating membrane to catecholarnines. Trandelenburg and 
Graefe (1975) demonstrated that inhibition of catechol-a-
methyl transferase (COMT) induces supersensitivity of the 
cat nictitating membrane in a highly specific manner. The 
effect is limited to the response to NE, the physiological 
neurotransmitter, and only after the reuptake mechanism of 
the presynaptic terminal has been impaired either by dener-
vation or cocaine. The hydrocortisone induced supersensi-
tivity possessed characteristics similar to that induced by 
a COMT inhibitor. It was suggested that, hydrocortisone 
induced supersensitivity by blocking the high affinity up-
take of NE into the high affinity methylation compartment, 
within which released catecholamines are actively being 
methylated by COMT (Trandelenburg and Graefe, 1975). 
There are several conceivable mechanisms for the de-
velopment of supersensitivity in a cholinergic junction. 
Examples of these mechanisms are: a loss in junctional cho-
linesterase content or activity, an increase in the amount 
of acetylcholine released per impulse and an increase in 
the responsiveness of the receptor to activation by ACh. 
It is interesting that the apparent mechanism for the de-
velopment of supersensitivity in denervated striated muscle 
is the proliferation of extrajunctional cholinergic recep-
tors (Axelsson and Thesleff, 1959). 
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SUPERSENSITIVITY OF CENTRAL DOPAMINE. RECEPTORS 
In contrast to the peripheral somatic and autonomic 
nervous systems, relatively few studies were reported which 
suggested the development of supersensitivity within the 
brain; most studies were primarily concerned with the dopa-
minergic system, and employed prolonged reductions of brain 
dopamine content to induce the supersensitivity. This ap-
proach was analogous to disuse supersensitivity in the 
periphery. Stalk and Rech (1967) utilized chronic reser-
pine treatment to reduce brain dopamine content; the treat-
ment led to the development of a supersensitive locomotor 
response to d-amphetamine, a dopamine releasing agent. 
Similarly, a prolonged dopamine depletion was induced by 
the dietary administration of o<... -methylparatyrosine, and it 
resulted in a supersensitive locomotor response to ephe-
drine (Dominic and Moore, 1969). Similarly, the prolonged 
reductions in rat brain dopamine induced by 6-0HDA also 
resulted in a supersensitive response to the dopamimetics, 
apomorphine and L-DOPA (Ungerstedt, 197la; Uretsky and 
Schoenfeld, 1971) • 
More recently, other laboratories have verified the 
induction of dopaminergic receptor supersensitivity induced 
either by ol-mpt, reserpine or 6-0HDA treatment (Friedman 
et al., 1976; Nahorski, 1975; Tarsy and Baldessarini, 1974; 
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Thornburg and Moore, 1975). Furthermore, persistent or 
acute blockade of dopaminergic receptors with neurolep-
tic agents also induced dopaminergic receptor supersensi-
tivity {Christensen et al., 1976; Jackson et al., 1975; 
von Voigtlander et al., 1975; Yarbrough, 1975). Agonist 
activation by L-DOPA of dopamine receptors during the 
period of ~-mpt treatment prevented the development of 
supersensitivity by ~-mpt (Gudelsky et al., 1975). 
Supersensitivity of "dopaminergic autoreceptors" is 
another related phenomenon. Dopamine receptors have been 
postulated to exist on the dopaminergic neuron; hence, 
they were called autoreceptors (Bunney and Aghajanian, 
1975). The dopaminergic autoreceptors have been postulated 
to be responsible for the suppression of firing by dopami-
metic agents of dopaminergic cells in the substantia nigra 
(Bunney and Aghajanian, 1975); the inhibition of dopamine 
turnover by apomorphine was also thought to be the result 
of the activation of dopaminergic autoreceptors (Roth et 
al., 1975). Chronic haloperidol treatment reduced the 
threshold dose of apomorphine required to reduce the turn-
over of dopamine; this effect may be an example of super-
sensitivity of the dopaminoceptive autoreceptors {Gianutsos 
et al., 1975). Moreover, the presence of presynaptic re-
ceptors may modulate the degree of supersensitivity evi-
denced by postsynaptic dopamine receptors. The evidence 
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for the modulation of postsynaptic receptor supersensi-
tivity by presynaptic dopamine receptors was provided by 
the enhancement of reserpine-elicited dopaminergic super-
sensitivity by repeated administration of apomorphine or 
~-methyl-p-tyrosine during the reserpinization (Friedman 
et al • , 19 7 6 ) • 
SUBSENSITIVITY OF CENTRAL DOPAMINE RECEPTORS 
Subsensitivity of dopaminergic receptors has also 
recently been suggested to occur. Apomorphine administra-
tion induced a hypothermic response in rodents; this re-
sponse was characterized by acute desensitization, as a 
single dose of apomorphine prevented subsequent doses of 
apomorphine from inducing hypothermia (Costentin et al., 
1975b}. The response was specific for dopamine receptors 
since the hypothermic responses to clonidine, oxotremorine 
and promethazine were not altered by prior treatment with 
apomorphine (Costentin et al., 1975b). Chronic haloperidol 
induced supersensitivity to the apomorphine induced hypo-
thermia (Costentin et al., 1975a). In contrast, 6-0HDA 
treatment induced a subsensitivity to the hypothermic re-
sponse to apomorphine (Costentin et al., 1975a}. 
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OVERUSE SUPERSENSITIVITY OF CENTRAL DOPAMINE RECEPTORS 
In addition to the concept of disuse supersensitiv-
ity, recent experimental findings have suggested the de-
velopment of overuse supersensitivity in central dopaminer-
gic systems (Klawans and Margolin, 1975) • The adminis-
tration of amphetamine on a chronic basis and in high doses 
produced an enhanced response to amphetamine and apomor-
phine (Klawans and Margolin, 1975). It was suggested that 
L-DOPA induced dyskinesias, amphetamine choreatic movements 
and amphetamine psychosis may be a result of supersensi-
tivity of dopaminergic receptors induced by their chronic 
excessive stimulation. The exact mechanism and implica-
tions of these findings remain obscure at present. More-
over, certain other amphetamine related phenomena must be 
excluded before overuse supersensitivity can be considered 
as a separate phenomenon. For example, amphetamine also 
produces supersensitivity of adrenergically innervated tis-
sue in the periphery; this has been classified as the pre-
synaptic type of supersensitivity, being due to ampheta-
mine's blockade of uptake of NE by the adrenergic neuron 
(De Moraes and Carvalho, 1971). It is doubtful that block-
ade of the presynaptic NE uptake mechanism by amphetamine 
could account for the development, after chronic ampheta-
mine treatment, of a supersensitive response to apomor-
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phine, since apomorphine does not depend upon presynaptic 
stores of catecholamines for its action (Ernst, 1967, 
1969). There also exists the problem of state dependency 
and drug conditioning phenomena which may mimic the devel-
opment of supersensitivity (Tilson and Rech, 19'73}. Fur-
thermore, chronic amphetamine treatment may induce dopa-
minergic receptor supersensitivity via a chronic catecho-
lamine depletion (Lewander, 1974; Tonge, 1974). Thus, 
the mechanism of amphetamine induced supersensitivity of 
central dopamine receptors remains to be placed in proper 
perspective with the other known effects of chronic amphet-
amine administration. 
In contrast, chronic amphetamine treatment may induce 
in the periphery a subsensitivity of noradrenoceptors which 
is evidenced as a decreased elevation of cyclic AMP by 
noradrenaline. The subsensitivity appeared to be specific 
since the cyclic AMP elevations induced by either dopamine, 
5-HT or adenosine remained unaffected by the chronic amphet-
amine treatment (Martres et al., 1975). Chronic amphetamine 
treatment has not yet been observed to induce receptor sub-
sensitivity in the CNS. 
SUPERSENSITIVITY OF CENTRAL NE RECEPTORS 
In addition to the studies on dopamine receptor 
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supersensitivity some investigations have been concerned 
with demonstrating the supersensitivity of central nor-
adrenergic receptors. These studies employed the technique 
of depletion of brain NE content to induce a disuse type 
of supersensitivity. For example, a supersensitive hypo-
thermic response to c~onidine was observed in. rats three 
months after 6-0HDA induced lesions of the ascending NE 
containing pathways (Zis and Fibiger, 1975). 
In another study, treatment with reserpine was re-
ported, after 24 hours, to induce a supersensitive response 
of brain stem neurons to microiontophoretically applied 
norepinephrine (Boakes et al., 1971). Although an effect 
similar to that of reserpine was expected neither the 
dopamine-~-hydroxylase inhibitor, FLA-63, nor the tyrosine 
hydroxylase inhibitor,«-mpt, were able to induce changes 
in brain stem neuronal firing rates (Boakes et al., 1971). 
Furthermore, a presynaptic as well as postsynaptic 
norepinephrine receptor supersensitivity has been suggested 
to occur in rat cerebral cortical slices following intra-
ventricular 6-0HDA treatment (Kalisker et al., 1973; Huang 
et al., 1973). An acute short lasting subsensitivity and 
longer lasting supersensitivity to NE has been described 
following reserpine (Palmer et al., 1975). A beta-adrener-
gic receptor has been described in the rat pineal gland 
which regulates the activity of N-acetyltransferase and 
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therefore the degree of melatonin synthesis (Brownstein et 
al., 1973). Supersensitivity of the pineal !'-adrenergic 
receptors has been demonstrated following denervation via 
a superior cervical ganglionectomy (Deguchi and Axelrod, 
1972), disuse via constant light, reserpinization or 6-0HDA 
treatment (Deguchi and Axelrod, 1973; Weiss and Strada, 
1972). Thus, supersensitivity of central noradrenergic 
catecholaminergic receptors has been demonstrated in a 
number of ways which primarily rely upon a diminution in 
the amount of stimulation of the catecholaminergic recep-
tors. 
SUPERSENSITIVITY OF CENTRAL ACh RECEPTORS 
In contrast to the numerous investigations of super-
sensitivity in the peripheral somatic and autonomic nervous 
systems, there are relatively few examples of supersensi-
tivity of the cholinoceptive neurons of the central nervous 
system. Chronic scopolamine administration induced a su~ 
persensitive hypothermic response to pilocarpine (Friedman 
et al., 1969). More directly, Bird and Aghajanian (1975) 
demonstrated a supersensitive response of cholinoceptive 
hippocampal pyramidal cells to acetylcholine following the 
destruction of a cholinergic input from the medial septal 
nucleus. Clinically, it has been suggested that the par• 
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kinsonian patient exhibits a supersensitivity to choliner-
gic agents; however, this supersensitivity has been sug-
gested to be due secondarily to the loss of dopaminergic 
input to the striatum (Weintraub and Van Woert, 1975). 
Evidence for a subsensitivity of central cholinergic 
receptors has also been accumulated. Tolerance develops to 
the disruptive effects of diisopropylflurophosphate (DFP) 
on fixed ratio (FR) responding; a hyposensitivity of choli-
nergic mechanisms has been postulated to account for the 
development of this tolerance (Russell et al.,l975). More-
over, chronic dopaminergic blockade with haloperidol de-
creased the locomotor depressant action of pilocarpine. 
This has been suggested to be an example of central choli-
nergic receptor subsensitivity (Gianutsos and Lal, 1976). 
SUPERSENSITIVITY OF CENTRAL SEROTONIN RECEPTORS 
The advent of investigations into supersensitivity of 
central serotonin receptors began with the use of 5,6-0HT 
(Barnes et al., 1973c; Longo et al., 1974), (cf. Discussion). 
DEMONSTRATING POSTSYNAPTIC SUPERSENSITIVITY OF CENTRAL DA 
AND NE RECEPTORS WITH THE MICROIONTOPHORETIC TECHNIQUE 
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Although the.re exists much indirect evidence suggest-
ing postsynaptic receptor supersensitivity in the central 
nervous system, it has not been unequivocally demonstrated 
by a direct technique. The direct method for the demon-
stration of supersensitivity to a neurotransmitter in the 
central nervous system involves the use of the microion-
tophoretic application of that neurotransmitter to its 
receptive cells. The major difficulty with the ionto-
phoretic technique in the central nervous system is that 
one can never be certain whether an observed response is 
the direct result of an interaction of the iontophoresed 
neurotransmitter with the postsynaptic receptor or whether 
it is the indirect result of an interaction of the ionto-
phoresed neurotransmitter with receptors on the presynaptic 
boutons which impinge upon that cell. This difficulty is 
primarily a result of the presence of a large number of 
synaptic contacts which impinge upon cells in the mammalian 
central nervous system. Thus,it would be difficult to dis-
tinguish presynaptic from postsynaptic forms of supersensi-
tivity in the CNS with this technique. 
These practical difficulties with the microionto-
phoretic technique were observed recently in the course of 
the attempts to demonstrate postsynaptic receptor supersen-
sitivity of central dopaminoceptive cells. The microion-
tophoretic application of dopamine to cells in the stria-
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tum, following dopamine depleting lesions, resulted in the 
description of both a subsensitivity as well as a supersen-
sitivity to dopamine. Spehlmann and Stahl (1974) reported 
a subsensitivity of dopaminoceptive cells in the corpus 
striatum following tegmental lesions in the cat. They 
found, in cats with tegmental lesions, fewer spontaneously 
firing cells which could be inhibited by dopamine. Fur-
thermore, in lesioned cats, the dopamine ejection current 
required to inhibit striatal cells was significantly great-
er than in non-lesioned cats. The subsensitivity to dopa-
mine was specific since after the tegmental lesion there 
were no significant changes in the striatal cells' re-
sponses to either GABA or L-glutamate. In contradiction to 
the findings of Spehlmann and Stahl (1974) , Yarbrough and 
Phillis (1975) reported a supersensitive response of dopa-
minoceptive cells following unilateral lesions of the sub-
stantia nigra in rats. The supersensitive response was 
demonstrated as an increased proportion of cells which were 
inhibited by dopamine following the lesion. In addition, 
Yarbrough and Phillis (1975) reported that following the 
substantia nigra lesion there was a significant decrease in 
the threshold current required for dopamine to inhibit the 
firing of glutamate stimulated caudatal cells. Similar 
supersensitivity of dopaminoceptive cells to dopamine has 
been reported by Feltz and De Champlain (1972) • A super-
40 
sensitive response of dopaminoceptive cells was also ob-
served following chronic haloperidol administration 
(Yarbrough, 1975). 
In the case of norepinephrine,microiontophoretic 
studies have suggested that after 6-0HDA a supersensitivity 
develops in cerebellar Purkinje cells (Hoffer et al., 1971) 
and hippocampal pyramidal cells (Segal and Bloom, 1974) to 
iontophoretically applied NE. Disconcerting however, were 
the findings of a supersensitive response of brain stem 
neurons to iontophoretic application of NE after reserpine, 
but not after FLA-63 or ~-mpt (Boakes et al., 1971). 
MECHANISMS OF SUPERSENSITIVITY PHENOMENA IN THE CNS 
In the central nervous system the mechanism of the 
supersensitivity phenomenon has only recently been a sub-
ject of investigation. It was expected that denervation of 
dopaminergic pathways could result in an increased activa-
tion of dopamine stimulated adenylate cyclase activity by 
exogenously administered dopamimetics. The increased acti-
vation of adenylate cyclase might be a mechanism of super-
sensitivity. Dopamine stimulated adenylate cyclase was 
postulated to be involved in central dopaminergic neuro-
transmission (Kebabian and Greengard, 1971). In fact,the 
activation of adenylate cyclase by dopamine was increased 
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following radio frequency or 6-0HDA induced lesions of the 
substantia nigra of rats (Mishra et al., 1974}. However, 
others could not confirm after intrastriatal 6-0HDA any 
' ' 
alteration in the DA stimulated activity of mouse striatal 
adenylate cyclase (Von Voigtlander et al., 1973}. Most 
recently, an endogenous protein activator which regulates 
adenylate cyclase and phosphodiesterase activities was 
increased after chronic treatment with either 0(-mpt, re-
serpine or haloperidol (Gnegy et al., 1976}; this activator 
might be involved in the development of dopamine receptor 
supersensitivity. Thus, it remains a problem for further 
research to determine the role of DA stimulated adenylate 
cyclase in dopamine receptor supersensitivity. 
There are several other mechanisms which speculative-
ly may be involved in the development of central dopamine 
receptor supersensitivity. Hormonal mechanisms may alter 
receptor responsiveness as was demonstrated for thyroxine 
and hypothalamic factors such as thyrotropin releasing 
factor (TRF} and melanocyte inhibiting factor (MIF} for 
responses to L-DOPA (Engstrom et al., 1974; Plotnikoff 
et al., 1971; Huidobro-Toro et al., 1975}. Since an in-
hibition of protein synthesis blocks the effects of L-DOPA, 
it may be speculated that an increase in protein synthesis 
may induce a supersensitive response to L-DOPA (Tang et 
al., 1974}. Decreases in either the amount or activity of 
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the recently discovered heat stable activator of phospho-
diesterase may also induce supersensitivity (Strada et al., 
1974). Moreover, the finding of prolonged activation of 
dopaminergic receptors by cholera toxin (Miller and Kelly, 
1975) and the increased sensitivity of mice to apomorphine 
and clonidine after repeated electroconvulsive shock 
(Modigh, 1975) suggest the possibility of other mechanisms 
which control central dopamine receptor sensitivity. In 
addition, other mechanisms, such as an increase in the 
amount of neurotransmitter released (Sharpless, 1975) or 
the taking over of function by another neurotransmitter 
system (Longo, 1975) were also suggested but not yet ex-
plored. 
In the central nervous system, the mechanism of 
changes in receptor sensitivity was most extensively in-
vestigated in the pineal gland. A beta-adrenergic receptor 
is thought to regulate the activity of N-acetyltransferase 
(NAT) in the pineal gland (Brownstein et al., 1973). In-
formation about environmental lighting is conveyed to the 
pineal via postganglionic sympathetic fibers which have 
their cell bodies located in the superior cervical ganglion 
(Kappers, 1960). Denervation via a bilateral superior cer-
vical ganglionectomy resulted in a superinduction of NAT 
activity by isoproterenol (Deguchi and Axelrod, 1972). The 
supersensitivity was characterized as the postsynaptic type 
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which occurred as soon as 24 hours following denervation 
(oeguchi and Axelrod, 1972) • Denervation of the pineal 
did not result in a supersensitive response to dibutyryl 
cyclic AMP. Thus, the mechanism of supersensitivity ap-
peared to be located before the cAMP,"second messenger" 
step (Deguchi and Axelrod, 1973) • Furthermore, a catecho-
lamine induced increase in cAMP could not account for the 
supersensitivity since a supersensitive response of adenyl 
cyclase to catecholamines did not occur until four weeks 
after denervation (Deguchi and Axelrod, 1973) • Thus, one 
may speculate that some other as yet undefined aspect of 
the NE-receptor interaction in the pineal could account for 
the supersensitivity observed after denervation. Possible, 
some involvement of both RNA and protein synthesis may be 
involved as in the case of the changes in the diurnal re-
sponsiveness of NAT to induction by catecholamines (Romero 
and Axelrod, 1975) • 
In other experiments the mechanism of supersensitiv-
ity to NE appeared to be more clearly related to an en-
hanced response of adenyl cyclase to norepinephrine and the 
subsequent elevation of cyclic AMP levels. For example, 
two independent groups have documented an enhanced accumu-
lation of cyclic 3'-5' AMP in rat cerebral cortical slices 
following intraventricular 6-0HDA treatment (Kalisker et 
al., 1973; Huang et al., 1973). In fact, both an early 
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developing prejunctional as well as a later developing 
postjunctional type of supersensitivity were suggested in 
this preparation. Thus, the development of supersensi-
tivity of rat cerebral cortical slices to NE partly re-
sembles that observed in sympathetically innervated periph-
eral tissues after a postganglionectomy (Trandelenburg, 
1966). 
In contrast to the catecholaminergic neurotransmit-
ter system, our understanding of the mechanism of supersen-
sitivity of central cholinoceptive receptor~ is minimal. 
At least in one case the central supersensitivity to choli-
nonimetics was shown to arise from a presynaptic loss of 
acetylcholinesterase (Bird and Aghajanian, 1975). Further-
more, we have practically no knowledge concerning the 
mechanisms of supersensitivity in central serotonin re-
ceptors. 
THE APPROACH TAKEN TO ASSESS THE SELECTIVITY OF THE NEURO-
TOXICITY OF 6-0HDA AND 5,6-0HT 
It can be expected on the basis of the preceeding dis-
cussion that a selective neurotoxin may induce, at a partic-
ular dose, the depletion of a single neurotransmitter. There-
fore, to neurochemically assess the selectivity of 6-0HDA 
and 5,6-0HT the brain content of four neurotraasmitters 
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was measured. The brain contents of norepinephrine, dopa-
mine, serotonin and acetylcholine were measured after each 
neurotoxin treatment in order to: a) verify the destruc-
tion of a particular neurotransmitter system as evidenced 
by a decline in the levels of DA and/or NE in the case of 
6-0HDA or 5-HT in the case of 5,6-0HT; b) to assess the 
selectivity of destruction by investigating alterations in 
the brain content of several other neurotransmitters such 
as ACh and 5-HT in the case of 6-0HDA and DA, NE and ACh in 
the case of 5,6-0HT. 
Since neuronal destruction is considered to result in 
changes in postsynaptic receptor sensitivity the use of 
postsynaptic agonists acting on the dopaminoceptive, sero-
tonoceptive or cholinoceptive receptor sites would help to 
elucidate the selectivity of neuronal destruction induced 
by either 6-0HDA or 5,6-0HT. 
The postsynaptic state of dopaminergic receptors was 
assessed by the use of apomorphine, a postulated direct DA 
receptor agonist (Ernst, 1969) • Since apomorphine is not 
taken up by dopaminergic nerve terminals it would not be 
useful to demonstrate supersensitivity of the prejunctional 
type. However, apomorphine would be useful in demonstrat-
ing DA receptor supersensitivity of the postsynaptic type. 
Thus, any 6-0HDA or 5,6-0HT induced increase in the behav-
ioral response to apomorphine was considered to be evidence 
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for the postsynaptic type of DA receptor supersensitivity. 
The behavioral response to L-DOPA was used to test 
for the presence of the presynaptic type of DA receptor 
supersensitivity as L-DOPA's action depends upon the forma-
tion of dopamine (Levitt et al., 1965) which may be taken 
up by dopaminergic nerve terminals. Thus,supersensitivity 
to L-DOPA but not to apomorphine would be indicative of 
a presynaptic type of DA receptor supersensitivity. 
Furthermore, as neuronal destruction may result in 
the development of subsensitivity, this was also evaluated 
in the case of the dopaminergic neurons with the use of 
methamphetamine. Since methamphetamine's action depends 
upon a presynaptic store of catecholamines (Moore et al., 
1970}, any decrease in the action of methamphetamine after 
neurotoxin treatment would be indicative of a presynaptic 
type of subsensitivity of dopamine receptors. 
To test for supersensitivity of serotonergic re-
ceptors the administration of L-5-HTP, which induced head 
twitches and tremors in mice (Corne, 1963) was utilized. 
It has been considered that the response to L-5-HTP is a 
result of 5-HT formed in the brain stem following its de-
carboxylation (Corne, 1963}. Moreover, the pharmacologic 
action of L-5-HTP does not depend upon the rate limiting 
tryptophan hydroxylase step of 5-HT synthesis (Grahame-
Smith, 1971). Thus, L-5-HTP could activate the postsynap-
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tic 5-HT receptors in the absence of serotonergic nerve 
terminals. However, any observed supersensitive response to 
L-5-HTP may also be of the presynaptic type; as in the ab-
sence of nerve terminals there would be impaired reuptake of 
the 5-HT formed from 5-HTP. In contrast, L-tryptophan would 
be a poor choice as an agonist to test for 5-HT receptor 
supersensitivity since it depends upon the presence of brain 
tryptophan hydroxylase which is located in the serotonergic 
neurons, and which may be depleted by neurotoxin treatments. 
In addition, the status of central muscarinic cho-
linoceptive receptors was assessed with tremorine, a com-
pound the action of which is believed to result from a 
direct interaction with that receptor {Everett and.Blockus, 
1956; Cox and Potkonjak, 1969b). Thus, any increase in the 
tremorigenic response to tremorine may reflect a supersen-
sitivity of central muscarinic cholinoceptive receptors. 
Behavioral analysis consisted of an examination of 
locomotor activity following administration of the neuro-
toxins since the catecholaminergic system appears to have 
a facilitatory role in this behavior. Destruction of the 
catecholaminergic system should be reflected as a depres-
sion of motor activity. Thus, changes in spontaneous loco-
motor activity may be a supportive argument but may not be 
the only argument {cf. above) indicative of a selective 
neurotoxin action on the catecholaminergic system. 
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Indeed, if either 6-0HDA or 5,6-0HT changed the brain con-
tent of more than one neurotransmitter, or changed the sen-
sitivity of more than one postsynaptic receptor, then 6-0HDA 
or 5,6-0HT may be classified as non-specific neurotoxins and 
possibly as non-selective neurotoxins. All results must al-
so be interpreted to account for possible direct interac-
tions or interrelationships between several neurotransmitter 
systems. Such interactions may mimic a non-specific action 
and must be excluded as the causal factors of multineuro-
transmitter changes that can be observed following neuro-
toxin treatment. 
Regeneration of axons and axon terminals was reported 
following 6-0HDA or 5,6-0HT treatments (cf. below). In the 
case of 6-0HDA, De Champlain (1971) reported a regrowth of 
adrenergic fibers in the rat after systemic administration 
of 6-0HDA. The regeneration of monaminergic neurons after 
6-0HDA was also observed in the central nervous system 
(Nygren et al., 1971). Similarly, regeneration and sprout-
ing was observed following 5,6-0HT treatment (Bjorklund 
et al., 1973; Nobin et al., 1973). In the case of 5,6-0HT 
treatment it was suggested that a functional serotonergic 
reinervation takes place (Fuxe et al., 1973) long after the 
5,6-0HT treatment. Because of the regeneration phenomena, 
the aforementioned pharmacological, neurochemical and 
behavioral tests were investigated at various times 
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after the administration of either 6-0HDA or 5,6-0HT in 
order to determine the permanence of any observed al-
terations in receptor sensitivity. 
The following pages report the findings of this 
study as they relate to the selectivity of action of the 
neurotoxins 6-0HDA and 5,6-0HT after intracerebral adminis-
tration to mice. The neurochemical, behavioral and pharma-
cological approaches eluded to above were employed in this 
study to assess the selectivity of the aforementioned neu-
rotoxins. 
METHODS 
ANIMALS: AND INTRACEREBRAL 'IN'JECTION TECHNIQUE 
Male mice of the ICR strain (Indiana Farms) ranging 
in weight from 20 to 25 grams were used. Seven mice were 
housed per cage with food and water ad lib. The mice were 
maintained on a light-dark cycle of 14 hours of light 
(0600-2000 hrs.) and 10 hours of darkness (2000-0600 hrs.) 
throughout the study. 
Either 5,6-dihydroxytryptamine (5,6-0HT), 6-hydroxy-
dopamine (6-0HDA) or the vehicle were injected intracere-
brally as described by Haley and Me Cormick (1957). The 
drugs were always injected in a volume of ten microliters 
using 2.5 rnm long 27 gauge stainless steel needle attached 
to a 50 f{ 1 Hamil ton microsyringe; the tip of the needle 
was ground to a slight (0.25 rnm} bevel. 5,6-0HT and 6-0HDA 
were freshly prepared prior to injection in a 1:1000 aque-
ous ascorbic acid solution. 5,6-0HT or 6-0HDA were admin-
istered at the doses of 43 and 70 ~gm of the base, respec-
tively. These doses were found to produce gross behavioral 
changes in pilot experiments. They were also reported to 
be without extensive lethality and were used successfully 
in rats. 
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India ink, 10 microliters, was used to determine the 
distribution of the drug solution following the intracere-
bral injection (Haley and Me Cormick, 1957). India ink was 
found throughout the ventricular system and the surface of 
the cortical areas. It was assumed that the drug injec-
tions had a similar distribution pattern. It was further 
assumed that the. uptake mechanism of the catecholamine con-
taining nerve terminals and the distribution of the in-
jected drugs were the critical factors with regard to their 
destruction. 
The site of the intracerebral injection was estimated 
in mice sacrificed for neurochemical evaluation. The site 
of injection was found to be 1.7 ~ 0.06 rnrn {S. E.) lateral 
to the sagittal suture and 0.35 ~ 0.08 mrn (S. E.) posterior 
to an imaginary perpendicular to the sagittal suture; the 
perpendicular intersected the sagittal suture at the point 
where the left and right coronal sutures intersected the 
sagittal suture (100 animals). On average, the tip of the 
injection cannula was located in the right lateral ven-
tricle. When the ventricle was missed the other structures 
receiving the injection were primarily the lateral septum 
and the putamen. 
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l?lfA:RMACOLOGICAL AND. BEHAVIORAL TESTS 
LOCOMOTOR ACTIVITY 
Leigh Valley photoactometers were used to quantify 
the locomotor activity of mice. Groups of six mice were 
placed in photoactometers and their activity was recorded 
every fifteen minutes for three hours. 
In order to evaluate the effect of 6-0HDA and 5,6-
0HT on locomotor activity following their intracerebral in-
jection, two types of experiments were performed. One 
measurement of activity following the treatment with either 
6-0HDA, 5,6-0HT or vehicle involved the repeated assessment 
of locomotion on alternate days for a total of 20 days 
after intracerebral injection. Another approach, designed 
to negate the conditioning effect of repeated measures of 
motor activity, involved the single assessment of motor 
activity in different groups of naive animals 1, 4, 10 and 
20 days after intracerebral injection. 
LOCOMOTOR RESPONSES TO METHAMPHETAMINE. AND" L·-DOPA 
The locomotor response to methamphetamine, 2.5 mg/kg, 
i.p., was recorded in a similar fashion (cf. above) utiliz-
ing repeated measures of locomotor activity in the same 
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group as well as single measures in different groups of 
mice. The locomotor activity was recorded every 15 minutes 
for 90 minutes prior to and 90 minutes subsequent to the 
administration of methamphetamine. 
The locomotor response of 5,6-0HT, 6-0HDA and vehicle 
treated mice to L-DOPA (100 mg/kg, i.p.) were recorded in a 
similar fashion; a 90 minute pre L-DOPA measurement was 
combined with a 90 minute post L-DOPA measurement. The 
tests were carried out on the same groups of animals 1, 4, 
10, and 20 days after intracerebral injection. 
EVERETT TEST 
While a monoamine oxidase inhibitor, pargyline, was 
utilized by Everett; it was not utilized in this present 
investigation. Evaluation of the behavior response of 5,6-
0HT, 6-0HDA and vehicle treated mice to L-DOPA, 100 mg/kg, 
i.p., was carried out by means of the test introduced by 
Everett (1962, 1967). Everett's scoring system was em-
ployed. Mice were placed in groups of four per cage after 
L-DOPA administration, 100 mg/kg, i.p., and observed every 
ten minutes for one hour. The score of 1+, 2+ and 3+ were 
assigned to each animal. The evaluation was based on the 
presence of piloerection, exophthalmos, salivation, Straub 
tail grades, reactivity to external stimulation (character-
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ized by jumping, squeaking and kicking), and of aggressive 
and stereotypic behaviors. For each group of mice the per-
centage of animals exhibiting a maximal score of 1+, 2+ and 
3+ was calculated. 
All mice were scored after 100 mg/kg, i.p. of L-DOPA. 
The 1+ response. consisted of none or slight salivation, a 
slight or no increase in locomotor activity, and Straub 
tail grade +1 or +2. The mouse was classified as having 
Straub tail grade +1 when it held its tail parallel to the 
horizontal surface with the tip pointing caudally. The 
mouse was classified as having Straub tail grade +2 when 
it held its tail erect and perpendicular to the horizontal 
surface. The vehicle treated mice typically would show 
the 1+ response. 
The 2+ response to L-DOPA consisted of distinct 
salivation, a definite increase in motor activity, Straub 
tail grade +3, and increased reactivity to external stimuli 
characterized by darting or aggressive posturing. The 
mouse was classified as having Straub tail grade +3 when it 
held its tail arched over its back and with the tip point-
ing rostrally. The 2+ response to DOPA was observed only 
occasionally in vehicle treated mice, primarily at the 
early time after intracerebral injection, eg. 4 hours. 
The 3+ response to L-DOPA, 100 mg/kg, i.p., consisted 
of marked salivation, a marked increase in locomotion 
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characterized by episodic or continuous running or darting, 
Straub tail grade +3, spontaneous jumping, stereotypic be-
havior, aggressive posturing and marked hyperirritability 
expressed by squeaking, jumping, kicking, darting, running 
and aggressive attack in response to external stimuli. The 
external stimuli consisted of lifting the cage top and 
lightly touching the side of each mouse with the side of a 
glass stirring rod. Mice which did not exhibit hyperirri-
tability would tolerate the external stimuli, as following 
the stimulus, the mouse would walk away and resettle in a 
different corner of the cage. Vehicle treated mice never 
exhibited 3+ L-DOPA response. 
BEHAVIORAL RESPONSE TO APOMORPHINE 
The response of 5,6-0HT, 6-0HDA and vehicle treated 
mice to apomorphine, 40 mg/kg, i.p., was evaluated by ob-
serving spontaneous jumping, stereotypic climbing behavior, 
rigid gait, mouthing of sawdust and licking of the cage; in 
addition, some mice reacted to external stimuli by jumping, 
kicking and running. In an all or none fashion, the per-
centage of mice exhibiting hyperreactivity (the running, 
kicking and jumping response to external stimuli) and/or 
spontaneous jumping behavior were recorded and classified 
as having a supersensitive response to apomorphine. In 
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contrast to the supersensitive response of neurotoxin 
pretreated mice,the vehicle treated animals exhibited only 
stereotypic climbing behavior, licking of the cage and 
mouthing of sawdust along with slightly increased motor 
activity. Observation continued for one hour after apo-
morphine; after this time the mice appeared normal. 
QUANTIFICATION OF TREMORS 
Tremors elicited by tremorine (10 mg/kg, i.p.) or 
L-5-HTP (200 mg/kg) were quantified 4 days, 10 days and 
20 days following intracerebral injection of 6-0HDA, 5,6-
0HT or ascorbic acid vehicle. A single mouse was placed 
in a small plastic cage, suspended from a Grass FT-10 
force transducer. The tremors were recorded on one chan-
nel of a Beckman Dynograph and integrated on another chan-
nel. The average number of integrator resets per minute 
during four respective five minute periods was calculated 
for each animal 5, 15,30 and 60 minutes following the ad-
ministration of either tremorine or L-5-HTP. The neuro-
toxin induced changes in the tremorigenic effect of trem-
orine were estimated by comparing the mean integrated 
tremor responses for each of the three groups. 
Besides inducing tremor, L-5-HTP administration (200 
mg/kg, i.p.) elicited additional symptoms which included 
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head-shaking, abnormal gait and body position (spread eagle 
posture) and retrograde movements; marked flushing of ears 
and paws could be readily observed; finally, when 5-HTP 
was given to 5,6-0HT pretreated mice, death occasionally 
resulted. The fraction of animals in which the presence or 
absence of these symptoms could be observed was evaluated 
in 5,6-0HT and vehicle pretreated animals following 5-HTP 
challenge both in the presence or absence of a decarboxy-
lase inhibitor, RO 4-4602/1. 
NEUROCHEMICAL METHODS 
For the measurement of the bioamines the mice were 
sacrificed by decapitation, always between 7:00 and 11:00 
A.M. to minimize diurnal influences. Brain levels of dopa-
mine (DA) , norepinephrine (NE) , serotonin (5-HT) and 
acetylcholine (ACh) were measured in the portion of the 
brain composed of the cerebral hemispheres, basal ganglia, 
thalamus, hypothalamus, corpora quadrigemina and midbrain; 
the olfactory bulbs, cerebellum, pons and medulla were dis-
carded (Figure 1). The sample was rinsed, blotted, weighed 
and placed in a liquid nitrogen within one minute of 
decapitation. 
A modification of the ion exchange-column chroma-
tographic method of Atack and Magnusson (1970) was used for 
I 
I 
FIGURE 1. A sagittal view of the mouse brain. The dashed lines indicate 
the planes in which cuts were made to isolate the brain part used for 
neurochemical analysis. The portion of tissue between the dashed lines 
was used for the analysis. 
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the separation of NE, DA and 5-HT. Essentially, the spec-
trophotoflurometic methods of Bertler et al. (1958a, b), 
Carlsson and Waldeck (1958) and Maickel et al. (1967) were 
employed for the determination of NE, DA and 5-HT, respec-
tively as described in detail below. Four brains were 
pooled for each determination of NE, DA and 5-HT. 
After extraction with formic acid and electrophoretic 
separation, ACh was determined by the choline kinase method 
of Reid et al. (1971) as described in detail below. ACh 
determinations were carried out on single brains. 
EXTRACTION OF THE CATECHOLAMINES AND SEROTONIN 
The tissue was homogenized in 7.8 ml of 0.4 N per-
chloric acid (PCA) and 0.2 ml of 2% ascorbic acid; an ad-
ditional 3 ml of 0.4 perchloric acid (PCA) was used to 
rinse the homogenizing pestle into the centrifuge tube. 
The homogenate was kept on ice and centrifuged at 3,000 RPM 
for 15 minutes. The supernatant was decanted and filtered 
through Whatman glass fiber filter paper. The filtrate 
volume was recorded and each sample was adjusted to pH 6.5. 
The neutralized extract was placed in -4 ~ cold for 10 
minutes. Following cooling the samples were centrifuged 
for 10 minutes at 3,000 RPM. The resultant supernatant was 
decanted onto the previously prepared columns utilizing the 
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procedure of Bertler et al. (1958). 
pREPARATION OF RESIN FOR THE ELUTION OF CATECHOLAMINES AND 
SEROTONIN 
The BioRad AG50W -4X, 200-400 mesh H+ form (Strong 
cation Exchange) resin was batch processed in the following 
way prior to the preparation of the columns. 100 Gms. of 
resin was stirred with 100 ml of 2 N NaOH for 20 minutes. 
Triple distilled water was used in 100 ml quantities to 
wash away the NaOH until the final pH was less than 9.5. 
Subsequently, 100 ml of 2 N HCl was stirred with the resin 
for 20 minutes. This was followed by triple distilled 
water washes until the pH was greater than 5. The final 
washing was with 100 ml of redistilled ethanol; the mix-
ture was stirred for 20 minutes, followed by triple dis-
tilled water washes until the odor of ethanol was no longer 
apparent. The resin was packed into columns with triple 
distilled water. A volume of 20 ml of 0.1 M phosphate 
buffer at pH 6.5 containing 0.1% EDTA was passed through 
each column prior to use. The elution procedure described 
below was followed. 
61 
ELUTION OF THE CATECHOLAMINES AND SEROTONIN 
The amines were eluted according to the method of 
Atack and Magnusson (1970) • 
The sample was passed through the BioRad AGSOW resin 
(4X, 200-400 mesh) at 1 drop per 10 seconds followed by 
40 ml of triple glass distilled water at 1 drop every 5 
seconds. Eleven ml of 1 N HCl was added and allowed to 
flow at 1 drop per 10 seconds. The first 3 ml of this HCl 
eluate were discarded and the subsequent 8 ml were col-
lected and contained NE. 
Following the elution of NE 13 ml of 1 N (50% ethane-
lie} HCl was allowed to pass through the column at a flow 
rate of 1 drop per 7 seconds. The first ml of the ethane-
lie HCl eluate was discarded. The next 5 ml were collected 
and contained DA; the next 7 ml were also collected and 
contained 5-HT. 
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ASSAY OF NOREPINEPHRINE 
The trihydroxyindole technique of Bertler et al. 
(1958) was used. The following protocol was used. 
STANDARD REAGENT TISSUE INTERNAL TISSUE 
BLANK SAMPLE STANDARD BLANK 
distilled H2o 3.80 3.90 2.90 2.80 2.90 
0.1 M PO 0.50 0.50 0.50 0.50 0.50 
buffer pa 6.5 
sample eluate 1.00 1.00 1.00 
at pH 6.5 
NE standard 0.10 0.10 
(Lc.c.gm/ml) 
0.5% ZnS04 0.05 0.05 0.05 0.05 0.05 
0.25% 0.05 0.05 0.05 0.05 0.05 
K3Fe(CN) 6 
5 MINUTE WAIT 
2% ascorbic 0.50 0.50 0.50 0.50 
acid, 5N NaOH 
5N NaOH 0.45 
10 MINUTE' WAIT 
2% ascorbic 0.05 
acid 
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samples were placed in an Aminco Bowman spectrophoto-
fluorometer and read with wave lengths for excitation of 
400 m~ and for emission of 50 5 mx. • 
ASSAY OF DOPAMINE 
A modification of the dihydroxyindole technique of 
Carlsson and Waldeck (1958) as modified by Glisson et al. 
(1972) was used. The following protocol was used for the 
development of the fluorophore. 
50% Ethanolic 
HCl lN pH 5.4 
distilled H2o. 
citrate P04 
buffer pH 5.4 
DA standard 
(1 )(gm/ml) 
sample (un-
neutralized) 
sample-pH 5.4 
NaS03-NaOH 
0.02 N Iodine 
5N Acetic Acid 
STANDARD REAGENT TISSUE 
BLANK SAMPLE 
2.00 2.00 
1.05 1.30 1.30 
0.50 0.50 0.50 
0.25 
2.00 
0.10 0.10 0.10 
5 MINUTE WAIT 
0.50 0.50 0.50 
5 MINUTE WAIT 
1.60 1.60 1.60 
INTERNAL TISSUE 
STANDARD BLANK 
1.05 1.30 
0.50 0.50 
0.25 
1.65 
2.00 
0.50 
0.10 0.10 
0.50 
1.60 1.60 
0.35 
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samples were heated at 100° C for fifteen minutes, cooled 
and the fluorescence read in an Aminco Bowman spectrophoto-
fluorometer. The fluorescence wave lengths used were 330 
m~ for excitation and 380 m~ for emission. 
ASSAY OF SEROTONIN 
The o-phthalaldehyde {OPT) technique of Maickel et 
al. {1968} was used. Briefly, 0.5 ml of the 5-HT eluate 
was mixed with 1 ml of 4 mg% OPT in 10 N HCl. The resul-
tant mixture was heated at 100°C for ten minutes, cooled to 
room temperature and read in the Aminco Bowman spectro-
photofuorometer with the wave lengths of excitation at 
360 mM. and emission at 4 70 m)A. • The slit arrangement used 
was: excitation slit 2, cuvette slit 5, emission cuvette 
slit 2, emission slit 5, phototube slit 1. 
EXTRACTION AND ASSAY OF ACETYLCHOLINE 
The technique of Haubrich and Reid {1973} was 
utilized. The ACh and choline were extracted from brain 
tissue with a 15% solution of lN formic acid in acetone 
(5 ml per gram of tissue) • A second extraction was carried 
out with a 10% solution of lN formic acid in acetone {1 ml 
per gram of tissue) . The two extract supernants were com-
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bined with an equal volume of water saturated ether and 
shaken to extract the acetone into the ether. The organic 
layer was then aspirated and discarded. The solvents re-
maining in the aqueous phase were blown off with a stream 
of air. After the extract was centrifuged to remove par-
ticulate matter the resulting supernatant was lyophylized. 
The lyophylized extract was then dissolved in 20 ml 
of distilled water. 15 ml of the clear redissolved extract 
was spotted in three equal aliquots on Whatman 3 MM chroma-
tographic paper allowing for drying between each spotting. 
The paper was also spotted with marker spots of choline 
and acetylcholine as well as internal standards. The paper 
was placed in a flat plate electrophoresis unit with the 
origin toward the positive electrode. The paper then was 
moistened with a brush so that the electrophoresis pyri-
dine - formic acid buffer approached each side of the 
origin simultaneously. The electrophoresis unit was set to 
run at 800 volts for 2-3 hours. 
Following electrophoresis the paper was air dried. 
The marker spots were identified by exposure to iodine 
vapor. After marking the location of these spots with a 
pencil the iodine was removed from the paper by exposure to 
steam. A 20x25 mm template was used to mark off the sample 
spots. The paper was cut and rolled into a tight cylinder 
with forceps. One ml of distilled water was added to a 
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culture tube containing the paper to elute the choline and 
acetylcholine by agitating with a vortex mixer for one 
minute and allowing it to stand for fifteen minutes. 
Acetylcholine was hydrolysed as a 0.5 ml aliquot 
of the electrophoresis paper eluate was mixed with 10 ~1 
of concentrated ammonium hydroxide. The resultant mixture 
was heated for twenty minutes on a boiling water bath. The 
samples were then dried in a vacuum at 50-60°C. 
Following drying, 0.1 ml of a choline kinase and ATP 
solution containing ATP- A-32 P (yielding approximately 
1x105 - 3xlo 5 CPM per 0.1 ml) was added to the sample 
tubes. The tubes were agitated to dissolve the choline. 
The samples were then incubated at 37°C for 2 to 4 hours. 
Ten ~1 containing 100 ~g of phosphorylcholine chloride 
was added to each sample as a carrier. 1.5 ml of pH 10-
Tris-Mgso4 buffer was also added to each sample. The con-
tents of the sample tubes were added to a column containing 
Dowex I anion exchange resin (chloride form, 8% cross link-
ed, dry mesh 200-400). An additional 4.5 ml of pH 10-Tris-
Mgso4 buffer was also added to the column as a wash. The 
total effluent and eluate were collected and counted in a 
liquid scintillation counter. The brain content of ACh was 
calculated using the internal and external standards pro-
cessed in parallel with the samples. 
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DRUGS 
L-DOPA was dissolved with warming in sufficient 0.1 N 
HCl and distilled water to produce a 10 mg/ml solution at 
pH 3.5; RO 4-4602/1 and L-5-HTP were dissolved in water 
with warming. Tremorine HCl and methamphetamine HCl were 
dissolved in 0.9% saline. Apomorphine HCl was dissolved 
in 1:1,000 aqueous ascorbic acid. All drugs were adminis-
tered intraperitoneally. Methamphetamine HCl, L-DOPA, L-5-
HTP and DL-alpha-methyl tyrosine methyl ester HCl were 
purchased from the Sigma Chemical Company. RO 4-4602/1 
and tremorine were graciously supplied by Roche, Inc., 
Nutley, New Jersey and Abbott Labs, Abbott Park, Illinois 
respectively. Apomorphine HCl was purchased from Merck, 
Inc. Commercially available USP grade ascorbic acid was 
employed. Both 6-hydroxydopamine HBr and 5,6-dihydroxy-
tryptamine creatinine sulfate dihydrate were purchased from 
the Regis Chemical Company, Morton Grove, Illinois. 
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STATISTICS 
Dr. T. Hoffman of the biostatistical department of 
Lederle Laboratory in Pearl River, New York served as the 
statistical consultant. The following statistical proce-
dures were utilized. The "SAS" statistical analysis system 
developed by Anthony James Barr and James Howard Goodnight 
of the Department of Statistics, North Carolina State Uni-
versity, Raleigh, North Carolina was utilized on an IBM 360 
computer. The neurochemical data were analysed by analysis 
of variance and multiple comparisons were made by means of 
the Newman-Keuls multiple range test. Repeated measures of 
motor activity were analysed by a least squares regression 
and analysis of variance. The locomotor activity data de-
rived from the single test procedure were also analysed by 
analysis of variance and the mean activity of the groups 
were compared with the Newman-Keuls multiple range test. 
Significance of the occurrence of supersensitivity was 
assessed in both the Everett test and the apomorphine chal-
lenge test by means of the Chi-square statistic. The quan-
titative integrated readings of tremorigenic activity fol-
lowing either oxotremorine or L-5-HTP were analysed by 
means of the Mann Whitney U-test as well as the Kruskal-
Wallis test. 
RESULTS 
NEUROCHEMICAL FINDINGS 
The values for the various arnines were determined 
in the contiguous brain part which included the cerebral 
hemispheres, basal ganglia, thalamus, hypothalamus, corpora 
quadrigemina and midbrain, hereafter referred to as 
"brain"; the brain parts which were not analyzed were the 
olfactory bulbs, cerebellum and pons-medulla (Figure 1}. 
SEROTONIN 
Mouse brain levels of serotonin were altered by the 
intracerebral administration of either 6-0HDA or 5,6-0HT. 
The brain levels of 5-HT in vehicle treated mice were not 
found to differ significantly on any of the days tested. 
When compared to the vehicle treated animals, both 6-0HDA 
and 5,6-0HT significantly decreased the brain levels of 
serotonin; these decreased serotonin levels were observed 
on each of the days tested. Four, 10 and 20 days after 
the intracerebral injection of 70 ~gm of 6-0HDA, mouse 
brain levels of 5-HT were decreased by 22% (p~0.05}, 39% 
{p£.0.01) and 38% (p (.0.01), respectively. On the 4th, 
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TABLE 1 
BRAIN LEVELS (IN MICROGM/GM) OF DA, NE AND 5-HT FOLLOWING 
VEHICLE, 6-0HDA OR 5,6-0HT TREATMENT 
5-HT 
--
4 Da~s 10 Da;LS 20 Da~s 
A$C 0.49 + 0.03 (19) 0.59 + 0.03 (16) 0.55 + 0.02 {16) 
-
6-0HDA 0.38 + 0.03 (7) 0.36 + 0.05 (8) 0.34 + 0.01 (8) 
5,6-0HT 0.23 + 0.06 (12) 0.29 + 0.02 (8) 0.33 + 0.04 (8) 
DA 
-...) 
0 
ASC 1.22 + 0.18 (25) 1.24 + 0.09 (15) 1.04 + 0.08 (15) 
-
6-0HDA 0.46 + 0.10 (11) 0.37 + 0.06 (8) 0.59 + 0.06 (6) 
5,6-0HT 0.55 + 0.10 (16) 1.24 + 0.14 (7) 0.89 + 0.05 (8} 
NE 
ASC 0.56 + 0.01 (23) 0.54 + 0.01 (16) 0.52 + 0.05 (20} 
-
6-0HDA 0.05 + 0.01 (8) 0.20 + 0.01 (8} 0.14 + 0.01 (13) 
5,6-0HT 0.17 + 0.03 (15) 0.46 + 0.03 (8) 0.62 + 0.12 (8} 
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LEGEND FOR TABLE 1. 
Mouse brain levels of 5-HT, DA, and NE in ~gm/gm 
wet weight on various days after an intracerebral injection 
with either 6-0HDA, 5,6-0HT or ascorbic acid vehicle. Four 
brains were pooled for each determination. The number of 
determinations are indicated within the parenthesis. Sig-
nificance of differences were determined by the Newman-
Keuls multiple range test. 
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10th and 20th days after the intracerebral injection of 
43 Agm of 5,6-0HT, the mouse brain levels of 5-HT were 
found to be decreased by 53% (p < 0. 01) , 51% (p ( 0. 01) and 
40% (p<.O.Ol), respectively. There were no significant 
differences in the degree of serotonin depletion on the 
4th, lOth or 20th days after 6-0HDA. Furthermore, there 
were no significant differences in the degree of serotonin 
depletion on the 4th, lOth and 20th days after 5,6-0HT 
(Table 1). Thus, both 6-0HDA and 5,6-0HT treatments re-
sulted in prolonged decreases in mouse brain serotonin 
content. 
DOPAMINE 
Mouse brain levels of DA were differentially altered 
by the intracerebral injection of either 6-0HDA or 5,6-0HT. 
The levels of DA in vehicle treated mice were not found to 
differ significantly from each other on any of the days 
tested. Four, 10 and 20 days after the intracerebral in-
jection of 70~gm of 6-0HDA, the mouse brain levels of DA 
were 62%, 70% and 43% below the levels observed in the 
vehicle treated mice, respectively. These reductions in 
brain DA levels by 6-0HDA were at the p < 0. 01 level of 
statistical significance. Furthermore, the decreased brain 
DA levels which were observed in the 6-0HDA treated animals 
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on the 4th, lOth and 20th post-treatment days did not dif-
fer significantly from each other. Thus, the intracerebral 
injection of 6-0HDA induced a prolonged and sustained de-
pletion of DA in the mouse brain. 
The depletion of brain DA by the 5,6-0HT treatment 
was not as long lasting as that induced by the 6-0HDA 
treatment (Table 1) • Only on the 4th day after the intra-
cerebral injection of 43 ~gm of 5,6-0HT, was the mouse 
brain level of DA significantly below that of the vehicle 
treated mice (p <. 0. 01) • Furthermore, on the. lOth and 20th 
days after 5,6-0HT treatment, the level of DA was signifi-
cantly greater than that observed on the 4th day after 
5,6-0HT treatment (p < 0.05). 
NOREPINEPHRINE 
The level of NE in vehicle treated mice was not found 
to differ significantly on any of the days tested. Mouse 
brain levels of NE were differentially altered after the 
intracerebral injection of either 6-0HDA or 5,6-0HT. In 
those mice which had received the 6-0HDA treatment, the 
levels of NE in brain were significantly below those of 
mice which had received isovolumetric, intracerebral in-
jections of the ascorbic acid vehicle. The 6-0HDA treat-
ment resulted in reductions of the NE content in brain by 
74 
91%, 63% and 73% respectively, on the 4th, lOth and 20th 
days after the injection ( all the values were signifi-
cantly below the control values at the l.evel of p < 0. 01) • 
6-0HDA depleted the brain level of NE to a greater extent 
on the 4th as compared to the lOth post-treatment day 
(p ( 0 • 0 5) • Thus, 6-0HDA when administered intracerebrally 
to mice induces a prolonged depletion of brain NE content. 
Similar to the 5,6-0HT effect on the brain DA levels 
and as compared to the effect of 6-0HDA, the depletion of 
brain NE by the 5,6-0HT treatment was not as long lasting 
as that induced by the 6-0HDA treatment (Table 1) • The 
mouse brain level of NE was significantly below that of 
vehicle treated mice only on the 4th day after the intra-
cerebral injection of 5,6-0HT. Furthermore, the levels of 
NE in the 5,6-0HT treated mice were significantly greater 
on the lOth and 20th days after treatment than those ob-
served in mice which were tested 4 days after 5,6-0HT 
treatment. In addition, the levels of NE in the 5,6-0HT 
treated mice were also significantly greater than those 
observed in the 6-0HDA treated mice on both the lOth and 
20th post-treatment days. Therefore, 5,6-0HT treatment de-
pleted the brain content of NE in a transient manner with 
the levels returning to normal by the lOth day after treat-
ment. This transient effect of 5,6-0HT treatment on brain 
NE content is in direct contrast to the prolonged (up to 
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20 days) depletion of brain NE which was induced by the 
6-0HDA treatment. 
ACETYCHOLINE 
The intracerebral injection of 70 Aq.m of 6-0HDA or 
43 ){gin of 5, 6-0HT did not alter the mouse brain levels of 
ACh as compared to the vehicle treated mice (Table 2) • The 
ACh data obtained following 6-0HDA treatment with the elec-
trophoretic technique of Reid et al. (1971), confirm those 
previously reported by Barnes et al. (1973a, b) obtained 
with a bioassay method of ACh analysis. 
AMINES AFTER L-DOPA 
The i.p. administration of L-DOPA (100 mg/kg) lowered 
the brain 5-HT levels (p < 0. 0 5) of mice which had received, 
4 days earlier, an intracerebral injection of either ascor-
bic acid vehicle or 5,6-0HT (Table 3). L-DOPA did not 
appear to affect the brain levels of 5-HT in mice which had 
been pretreated with 6-0HDA. The 5-HT depleting action of 
L-DOPA has been previously reported (Bartholini, Da Prada 
and Pletscher, 1968; Butcher and Engel, 1969; Everett and 
Borcherding, 1970). 
The mouse brain levels of DA were significantly 
TABLE 2 
BRAIN LEVELS (IN NANOM/GM) OF ACH FOLLOWING 
6-0HDA AND 5,6-0HT TREATMENT 
4 DAYS 4 DAYS + L-DOPA 4 DAYS + 5-HTP 20 DAYS 
ASC 14.5 + 0.6 (22) 15.3 + 1.3 (16) 22.2 + 2.1 (17) 15.6 + 1.1 (19) 
6-0HDA 13.0 + 0.9 (11) 14.5 + 1.2 (12) 21.6 + 0.9 (11) 16.5 + 2.1 (12) 
5,6-0HT 16.4 + 1.4 (19) 15.6 + 1.3 (16) 16.3 + 2.5 (15) 15.8 + 0.9 (8) 
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LEGEND FOR TABLE 2. 
Mouse brain content of ACh in nM/Gm fresh weight 
4 and 20 days after the intracerebral injection of either 
6-0HDA (70 .A(gm/10 )..(1) , 5, 6-0HT ( 43 .L(gm/10 ..t( 1) or 10 ).(1 of 
o.l% ascorbic acid vehicle. Single mouse brains were used 
for each determination. The number of determinations are 
indicated in the parenthesis. Neither 6-0HDA nor 5,6-
0HT affected the levels of ACh 4 or 20 days after i.e. 
injection. L-DOPA 100 mg/kg, i.p. ,15 minutes prior to 
sacrifice did not affect the brain levels of ACh, in 
either 6-0HDA, 5,6-0HT or vehicle treated mice. L-5-HTP 
200 mg/kg, i.p. 15 minutes prior to sacrifice increased 
the brain levels of ACh in vehicle treated (ASC) and 
6-0HDA treated mice but not in 5,6-0HT treated mice 
(p<. 0.025). 
TABLE 3 
BRAIN LEVELS OF 5-HT, DA AND NE FOLLOWING THE ADMINISTRATION OF L-DOPA OR 5-HTP 
FOUR DAYS AFTER INTRACEREBRAL INJECTION OF VEHICLE, 6-0HDA OR 5,6-0HT 
4 DAYS 4 DAYS + L-DOPA 4 DAYS + L-5-HTP 
5-HT 
ASC 0.49 + 0.03 (19) 0.27 + 0.1 (19) 0.93 + 0.14 (16) 
6-0HDA 0.38 + 0.03 (7) 0.41 + 0.13 (8) 0.76 + 0.19 (8) 
5,6-0HT 0.23 + 0.06 (12) 0.10 + 0.01 (12) 0.70 + 0.17 (8) 
DA 
ASC 1.22 + 0.18 (25) 1.87 + 0.22 (24) 1.23 + 0.10 (14) 
6-0HDA 0.46 + 0.10 (11) 0.74 + 0.09 (7) 0.68 + 0.06 (8) -...! 00 5,6-0HT 0.55 + 0.10 (16) 1.60 + 0.24 (16) 1.31 + 0.08 (8) 
NE 
ASC 0.56 + 0.01 (23) 0.56 + 0.06 (24) 0.69 + 0.08 (18) 
6-0HDA 0.05 + 0.01 ( 8) 0.41 + 0.06 (8) 0.31 + 0.03 (12) 
5,6-0HT 0.17 + 0.03 (15) 0.26 + 0.03 (16) 0.37 + 0.04 (7) 
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LEGEND FOR TABLE 3. 
Mouse brain levels of NE, DA and 5-HT in ~gm/Gm. 
wet weight four days after intracerebral injection with 
either 6-0HDA, 5,6-0HT or ascorbic acid vehicle. Brain 
bioamine levels are also listed for animals which had 
received either L-DOPA, 100 mg/kg, i.p. or L-5-HTP, 200 
mg/kg, i.p. fifteen minutes prior to sacrifice. Four 
brains were pooled for each determination. The number of 
determinations are indicated within the parenthesis. 
Significance of differences were determined by the Newman-
Keuls multiple range test. 
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elevated (p ~0.01) 15 minutes after L-DOPA administration 
(100 mg/kg, i.p.) in mice which had received an intra-
cerebral injection, 4 days previously, of vehicle or 5,6-
0HT. Although the increase in brain dopamine after L-DOPA 
in 6-0HDA treated mice was not statistically significant in 
this study, we have previously reported (Barnes.et al., 
1973b) that L-DOPA can elevate the depleted brain levels 
of DA in 6-0HDA treated mice. The evidence indicates that 
L-DOPA treatment can increase the brain levels of DA in 
6-0HDA and 5,6-0HT treated mice, but the levels of DA did 
not exceed those of vehicle treated mice (Table 3) (Barnes 
et al., 1973b,c). Thus, the depletion of DA 4 days after 
intracerebral injection of 5,6-0HT and of 6-0HDA 2 and 10 
days after intracerebral injection can be antagonized and 
the DA somewhat elevated by L-DOPA administration. Without 
further studies it can not yet be established whether the 
maximal increases in brain DA induced by L-DOPA administra-
tion to vehicle treated mice can, in fact, be achieved in mice 
pretreated with the neurotoxins 6-0HDA or 5,6-0HT; no other 
published study has, as of yet, addressed itself to this 
question. 
The mouse brain levels of NE were also elevated 15 
minutes after L-DOPA administration (100 mg/kg, i.p.) in 
mice which had previously received an intracerebral in-
jection, 4 days earlier, of 6-0HDA (p( 0.05). After L-DOPA 
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administration the brain content of NE in· 6-0HDA treated 
mice was not significantly different from that of vehicle 
treated mice, suc;1gesting a restoration by. L-DOPA of the 
brain NE content of 6-0HDA treated mice to normal or near 
normal levels. Although the 5, 6-0HT treated animals also 
exhibited an increase in the brain content of NE after 
L-DOPA,. that increase was not statistically significant. In 
fact, after L-DOPA the 5,6-0HT treated mice still had a 
brain level of NE which was signif.icantly below that of 
vehicle treated mice {p£ 0.05) (Table 3). Control mice 
which were treated with the ascorbic acid vehicle. did not 
exhibit NE elevation after L-DOPA administrati.on. Thus, 
the difference in the capacity to restore .the brain content 
of NE of the 5,6-0HT and 6-0HDA treated mice in response to 
L-DOPA administration may, in part, explain the differences 
in behavioral response of these mice to L-DOPA; these re-
sults will be described in a subsequent section. 
The i.p. administration of L-DOPA (100 mg/kg) did not 
affect the brain content of ACh mice which had,. 4 days pre-
viously, received intracerebral injections of either 6-0HDA, 
5, 6-0HT or vehic.le . (Table 2) • 
AMINES AFTE'R 'S-HTP 
Fifteen minutes after the injection of L.-5-HTP {200 
82 
mg/kg, i.p.), the brain content of 5-HT was increased in 
mice which received, 4 days previously, an intracerebral 
injection of either vehicle, 6-0HDA or 5,6-0HT (Table 3). 
The L-5-HTP treatment increased the 5-HT content of vehicle 
treated mice by 90% (p <. 0. 01), of 6-0HDA treated mice by 
100% (p<O.OS) and of 5,6-0HT treated mice by 204% (p< 
0.01). Thus one may conclude that the pretreatment with 
either ascorbic acid vehicle, 6-0HDA or 5,6-0HT, in the 
dose employed, did not change the ability of L-5-HTP to 
increase the brain content of 5-HT. After L-5-HTP the 
levels of 5-HT in 6-0HDA or 5,6-0HT treated mice were not 
significantly different; a fact which may account for a 
lack of difference between these groups in their behavioral 
response to L-5-HTP (cf. below). 
L-5-HTP administration did not alter the levels of DA 
in mice which, 4 days earlier, received an intracerebral 
injection of vehicle or 6-0HDA. After L-5-HTP administra-
tion, the content of DA in brains of mice which received 
6-0HDA was still below that of mice had received vehicle 
treatment (p < 0 .05). An unusual result was that after 
L-5-HTP, the level of DA was increased in 5,6-0HT treated 
mice when compared to 5,6-0HT treated mice which were not 
given L-5-HTP. Everett (1974) had reported that 5-HTP does 
not markedly affect the levels of DA in mice which did not 
receive either 6-0HDA or 5,6-0HT. 
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Fifteen minutes after the administration of L-5-HTP 
(200 mg/kg, i.p.) the brain levels of NE were not signifi-
cantly altered in vehicle or 5,6-0HT treated mice. Although 
the brain NE content increased after L-5-HTP in 6-0HDA 
treated mice (p ~ 0. 05) the NE· level was still markedly be-
low that of mice which had received an intracerebral injec-
tion of the vehicle and, 4 days later, 5-HTP (p <. 0. 01) (Table 
3). Thus, L-5-HTP administration (200 mg/kg, i.p.) could 
not restore the brain content of NE to normal levels in mice 
which had been depleted of NE by prior intracerebral treat-
ment with either 6-0HDA or 5,6-0HT. 
L-5-HTP (200 mg/kg, i.p.) increased the mouse brain 
content of ACh in animals which had received, 4 days pre-
viously, an intracerebral injection of vehicle or 6-0HDA 
(Table 2). After L-5-HTP, the content of ACh in mouse brain 
was increased by 53% (p '0. 025) in vehicle treated animals 
and by 66% (p <. 0. 025) in 6-0HDA treated animals. L-5-HTP 
was without effect on the brain content of ACh in mice which, 
4 days previously, had received an intracerebral injection 
of 5,6-0HT (Table 2). These results suggest an interaction 
between the serotonergic and the cholinergic systems and 
require further study. 
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- BEHAVIORAL F'IND'INGS 
LOCOMOTOR ACTIVITY - SINGLE TEST PROCEDURE 
The locomotor activity of mice was assessed at 
various times after 6-0HDA, 5,6-0HT or vehicle treatment. 
In the single test procedure naive mice were exposed only 
once to the locomotor activity chamber. The locomotor 
activity of mice in the single test procedure was markedly 
depressed on the 1st day following the intracerebral injec-
tion of either 6-0HDA or 5,6-0HT in doses of 70 or 43 ~gm/ 
10 ~1, respectively {Figure 2). When compared on the 1st 
post-treatment day to the ascorbic acid treated groups, the 
6-0HDA and 5,6-0HT treated groups exhibited a depression of 
spontaneous locomotor activity which was statistically 
significant to the p<. 0.001 level. The activity of the 
6-0HDA treated groups were not significantly different from 
that of the vehicle treated animals on the 4th, lOth and 
20th post-treatment days. Thus, the locomotor activity of 
6-0HDA treated mice recovered completely by the 4th day 
after treatment. However, the depression of locomotor 
activity lasted longer in 5,6-0HT treated animals. Al-
though some recovery was evident as on day 4, the activity 
was significantly greater than on day 1 {p <. 0. 005), the 
5,6-0HT treated animals did not show any additional in-
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LEGEND FOR FIGURE 2. 
The cumulated locomotor activity of mice, recorded 
at fifteen minute intervals for three hours on various 
days following intracerebral injection of ascorbic acid 
vehicle (Asc), 6-0HDA or 5,6-0HT. Each point represents 
the mean locomotor activity of three groups of six mice; 
s.E.M. values are shown for the cumulative activity of 
180 minutes. Different groups of mice were employed on each 
day ("single test"). The Newman-Keuls multiple range 
test as applied to a two factor ANOV was used to determine 
the significance of the differences from control values 
at three hours. On day 1 both 5,6-0HT and 6-0HDA treated 
groups were significantly less active than controls 
(**; p < 0. 001) • Only the 5, 6-0HT treated mice were signif-
icantly less active than controls on days 4 and 10 (*: 
p < 0. OS); there were no significant differences between 
the three groups on day 20. 
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LEGEND FOR FIGURE 3. 
The locomotor activity of mice was recorded for a 
total of 90 minutes on various days after intracerebral 
injection of either ascorbic acid vehicle, 70 ~gm of 
6-0HDA or 43 ~gm of 5,6-0HT. The same mice were tested 
every other day beginning with the 1st day after intra-
cerebral injection ("repeated" test). Each point repre-
sents the mean locomotor activity of 3 groups of 6 mice. 
A least squares fit of a quadratic (parabolic} curve 
represents the regression observed for the Asc and the 
5,6-0HT groups (r-square = 0.9222 and 0.7978, respec-
tively} . A simple linear regression represents the 6-
0HDA regression (r-square = 0.5013}. The 6-0HDA treated 
groups were significantly below control (p ~ 0. 05) on each 
of the 19 days. The 5,6-0HT groups were significantly less 
than controls (p < 0. 05} up to the 5th day after intra-
cerebral injection. The 5,6-0HT and 6-0HDA treated groups 
were not significantly different from each other. 
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crease in activity between the 4th and lOth day. The data 
indicate that in the case of the 5,6-0HT treated mice, a 
full recovery of the spontaneous locomotor activity did not 
occur until sometime after the lOth post-treatment day. 
LOCOMOTOR ACTIVITY - REPEATED TEST PROCEDURE 
The results obtained with the repeated locomotor 
activity test (cf. Methods) were similar to those obtained 
with the single test procedure. A marked depression of 
spontaneous locomotor activity was observed on the lst day 
following the intracerebral injection of either 6-0HDA or 
5,6-0HT (Figure 3). The vehicle treated animals showed the 
expected habituation to the locomotor chamber, their loco-
motor activity decreasing throughout the 19 days of the 
experiment. In contrast, the marked initial reduction in 
locomotor activity exhibited by the 5,6-0HT treated mice on 
the lst day after 5,6-0HT was followed by a gradual in-
crease in activity until the 11th post-treatment day;subse-
quently, the locomotor activity began to decrease progres-
sively. This result can be construed as indicating a block 
of the habituation response by the 5,6-0HT pretreatment and/ 
or as a recovery from the effect of 5,6-0HT treatment. 
Similarly, in the repeated test design, the 6-0HDA treated 
animals showed a depression of locomotor activity through 
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the 19 days (Figure 3). Since the activity levels de-
creased each day after 6-0HDA treatment it seems that 
6-0HDA did not affect the habituation response (Figure 
3) . The spontaneous motor activity of the 6-0HDA treated 
groups were significantly below that of vehicle treated 
groups (p <. 0. OS) on each test day. However, the 5, 6-0HT 
treated groups were no longer significantly below vehicle 
treated animals on the 5th and subsequent days of testing. 
Finally, in the repeated measure design, there were 
no significant differences observed in the spontaneous 
motor activity between the 6-0HDA or 5,6-0HT treated mice 
on any post-injection day. 
PHARMACOLOGICAL FINDINGS 
LOCOMOTOR RESPONSE TO METHAMPHETAMINE - SINGLE TEST 
PROCEDURE 
The locomotor stimulation induced by 2.5 mg/kg of 
methamphetamine, i.p., was significantly less in animals 
-·. 
that were pretreated with 6-0HDA as compared to vehicle 
treated controls (Figure 4) • This marked reduction in 
activity was observed on the 1st (p 4C. 0. 005) as well as the 
4th, lOth (p<.O.OS) and 20th (p<O.OOS) days following the 
administration of 6-0HDA. 
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LEGEND FOR FIGURE' 4 • 
The cumulated locomotor activity of mice was recorded 
at 15 minute intervals for 90 minutes after methamphetamine 
(2.5 mg/kg) administration on several days after treatment 
with either ascorbic .acid vehicle (Asc), 6-0HDA or 5,6-0HT. 
Different gr.oups of mice were employed on each day ( "sing.le 
test"}. Each point represents mean locomotor act.ivity of 
3 groups of 6 mice. S • E. M. values are shown for the cumu-
lated locomotor act.ivity at 90 minutes. The Newman-Keuls 
multiple range test appli~d to a 2 factor ANOV was used to 
determine the significance of the diff·erences from control 
values at 90 minutes. The 5,6-0HT mice differed signifi-
cantly from controls on day 1, day 4 and day 20. 6-0HDA 
treated animals differed sign.ificantly from controls on 
each day tested (* p ~0.05, ** p~O.Ol, *** p L..005). 
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At certain times, the 5,6-0HT treated mice could be 
differentiated from the 6-0HDA treated animals with regard 
to their locomotor responses to methamphetamine. The 5,6-
0HT treated mice were similar to the 6-0HDA treated mice in 
their locomotor response to methamphetamine only on the 
1st day following the intracerebral injection of the neuro-
toxins; in both groups of animals locomotor stimulation 
induced by methamphetamine was markedly reduced (p < 0. 005) • 
However, on the subsequent testing days the 5,6-0HT treated 
mice exhibited locomotor stimulatory effects, in response 
to methamphetamine administration, which were greater than 
those of 6-0HDA treated animals. Additionally, on the 4th 
and 20th days after the intracerebral injection of 5,6-0HT, 
these animals exhibited an enhanced response to methamphe-
tamine; i.e. this response was greater than that observed 
in vehicle treated mice (p< 0.05 and<.O.Ol, respectively). 
Those mice which had received intracerebral injections of 
the ascorbic acid vehicle exhibited stable locomotor stim-
ulatory responses to methamphetamine on each of the days 
tested. 
LOCOMOTOR RESPONSE TO METHAMPHETAMINE - REPEATED TEST 
PROCEDURE 
Figure 5 depicts the daily locomotor stimulation 
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The cumulated locomotor activity of mice was recorded 
at 15 minute intervals for 90 minutes· after methamphetamine 
(.2.5 mg/kg) challenge on various days after. either ascorbic 
' ' ' 
acid. vehicle Asc 1 6-0HDA or 51 6-0HT. treatment. The same 
mice were tes.ted on alternate days ("repeated test"). 
Each point represents mean locomotor activity of 3 groups 
of 6 mice. A simple linear regression was fitted to the 
data of each group;. r-square for the 5 1 6-0HT was 0.7804 
(p /.. 0. 05). Tolerance to methamphetamine did not occur on 
this dose regimen s.ince the slopes. of the re·gression line 
of both the vehicle treated and the 6-0HDA treated groups 
were not significantly different from zero (i.e. the time 
effect curve was parallel to the X axis). The 5~6-0HT 
treated mice differed significantly from controls on 
days 1 thru 7; the response of 6-0HDA treated mice was 
significantly less than that of the controls on each of 
the days tested (p L 0 • 0 5) • The bar (I) represents + the 
SEM of the activity. 
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induced by the i.p. administration of methamphetamine 
(2.5 mg/kg) administered every other day to the same groups 
of mice which were previously treated with either 6-0HDA, 
5,6-0HT or vehicle. The figure depicts these results as 
linear regression curves fitted to the data by the least 
squares method. It is obvious that tolerance did not de-
velop in the vehicle treated mice to the locomotor stimula-
tory effects of methamphetamine as administered on this al-
ternate days schedule; the slope of the regression line was 
not significantly different from zero. Thus, the vehicle 
treated mice exhibited stable locomotor responses to meth-
amphetamine in the repeated test procedure. 
The 6-0HDA treated mice also exhibited stable loco-
motor responses to methamphetamine in the repeated test. 
The stability is evidenced by the slope of the regression 
line calculated for the 6-0HDA data, as the slope did not 
differ significantly from zero. As in the case of the 
single test procedure, the 6-0HDA treated mice exhibited a 
markedly diminished response to methamphetamine beginning 
on the first day after 6-0HDA, and continuing throughout 
the test period (p < 0. 05) • 
Similarly, the 5,6-0HT treated mice also exhibited a 
marked reduction in their locomotor response to ampheta-
mine on the 1st day after 5,6-0HT, substantiating the 
results observed with the single test procedure. However, 
97 
the 5,6-0HT treated mice exhibited in the repeated test 
procedure a response to methamphetamine which gradually 
approached that of the vehicle treated mice. Specifically, 
the 5,6-0HT treated mice exhibited on days 1, 3, 5 and 7 a 
locomotor response to methamphetamine which was signifi-
cantly less than that of vehicle treated mice; subsequent-
ly, there was no significant difference between these two 
groups. 
LOCOMOTOR RESPONSE TO L-DOPA 
The locomotor response of vehicle treated mice to 
L-DOPA (100 mg/kg, i.p.) was unremarkable and constant on 
each of the days tested (Figure 6). However, 6-0HDA pre-
treatment resulted in a marked increase in the locomotor 
response of mice to L-DOPA on the 1st, 4th, lOth and 20th 
days after intracerebral 6-0HDA treatment (p~O.OOl); in 
fact, 100 mg/kg of L-DOPA induced in 6-0HDA treated mice 
wild running and jumping behavior. 
In contrast to the 6-0HDA treated animals, the L-DOPA 
response of the 5,6-0HT treated mice resembled that of the 
vehicle treated mice. Except for an occasional mouse which 
exhibited some slight stimulation, the majority of 5,6-0HT 
treated animals did not exhibit responses which were dif-
ferent from vehicle treated mice. In fact, there were no 
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LEGEND FOR FIGURE 6. 
The cumulative locomotor activity of mice was record-
ed at 15 minute intervals after L-DOPA administration (100 
mg/kg, i.p.) on various days following intracerebral in-
jections of either ascorbic acid vehicle (Asc) , 70 ~gm of 
6-0HDA, or 43 ~gm of 5,6-0HT. The points represent the 
mean locomotor activity of 3 groups of 6 mice each (n = 18) 
under each treatment condition. S.E.M. values are shown 
for the cumulative mean locomotor activity at 90 minutes 
after L-DOPA. The 6-0HDA and 5,6-0HT treated groups were 
tested for significant differences from the vehicle treated 
mice at 90 minutes after L-DOPA. Asterisks indicate 
significant differences with respect to vehicle treated 
mice: * p~0.05; ** p~O.OOl; significance of differences 
were determined with the Newman-Keuls multiple range test 
applied to a ANOV. 
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statistically significant differences between 5,6-0HT and 
vehicle treated mice, in their locomotor response to L-DOPA 
on any of the post-treatment days. 
EVERETT TEST 
Initial experiments (Barnes et al., 1973b) indicat-
ed that L-DOPA, 100 mg/kg, i.p. when administered 8 hours 
after pargyline, 40 mg/kg, i.p., produced few signs in 
vehicle treated mice (piloerection, exopthalmos, grade:l 
Straub tail and a slight increase iri reactivity). However, 
L-DOPA administration to 6-0HDA-treated mice induced be-
havior previously described by Everett and Weigand (1962); 
this behavior was characterized by hyperreactivity, squeak-
ing, piloerection, exopthalmos, grade 3 Straub tail, spon-
taneous jumping and running; a few mice also exhibited ag-
gression and/or stereotypic behavior. It is important to 
note that even when 6-0HDA treated animals exhibited a 
marked depression of spontaneous motor activity e.g. on the 
1st and 2nd days after intracerebral injection of 6-0HDA, 
the administration of L-DOPA did not produce a return to 
normal behavior, but rather the hyperreactive,hyperirritable 
behavior described above (cf. Methods). It was also ob-
served (Barnes et al., 1973b) that pargyline pretreatment 
was not prerequisite for the response; accordingly, subse-
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TABLE 4 
RESPONSE TO L-DOPA CHALLENGE IN 6-0HDA TREATED MICE 
% OF POPULATION SHOWING THE RESPONSE 
TIME AFTER 
6 -OHDA TREATMENT . GROUP +1 +2 +3 
4 Hr Vehicle 40 60 0 
6-0HDA 22 44 33 
8 Hr Vehicle 50 40 10 
6-0HDA 7 7 86 
16 Hr Vehicle 29 57 14 
6-0HDA 7 7 86 
24 Hr Vehicle 40 40 20 
6-0HDA 0 29 71 
2 Days Vehicle 70 30 0 
6-0HDA 0 0 100 
10 Days Vehicle 100 0 0 
6-0HDA 0 10 90 
20 Days Vehicle 80 20 0 
6-0HDA 6 35 59 
30 Days Vehicle 100 0 0 
6-0HDA 0 25 75 
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LEGEND FOR TABLE 4. 
The average percentage of mice scoring +1, +2 or 
+3 in response to L-DOPA 100 mg/kg, i.p. at various times 
after 6-0HDA or vehicle treatment is tabulated. The hyper-
sensitive response to L-DOPA was observed as soon as four 
hours after intracerebral injection and seemed to be fully 
developed by eight hours. The response was evident through-
out the thirty day test period n= 16 per group at each 
time after intracerebral injection. 
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quent investigations were carried out without pargyline 
pretreatment. 
A time course evaluation was carried out to determine 
at what point the exaggerated response to L-DOPA may be 
demonstrated after intracerebral 6-0HDA; the results are 
illustrated in Table 4. The potentiation of the L-DOPA re-
sponse seemed evident as early as 4 hours following 6-0HDA 
treatment; it was obvious and marked 8 hours after 6-0HDA. 
The response persisted for at least 30 days following the 
intracerebral injection of 6-0HDA (Table 4) • 
A comparison was made between the L-DOPA responses 
of vehicle, 6-0HDA and 5,6-0HT treated mice. Mice typical-
ly exhibited a +1 response to L-DOPA whether tested 4, 10 
or 20 days after the vehicle pretreatment; only infrequent-
ly did a vehicle treated mouse exhibit a response as high 
as +2 (Table 5) . The exaggeration of the Everett test fol-
lowing 6-0HDA pretreatment described by Barnes et al. 
(1973b) was confirmed in the present experiments for the 
4th, lOth and 20th days following the 6-0HDA treatment. At 
these times, from 92 to 100% of L-DOPA challenged 6-0HDA 
treated mice exhibited a 3+ response. This difference in 
response of 6-0HDA and vehicle treated mice was statis-
tically significant (Table 5) • 
The response to L-DOPA of 6-0HDA pretreated animals 
differed from that recorded in the 5,6-0HT treated animals. 
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TABLE 5 
RESPONSE TO L-DOPA IN. 5,, 6-0HT OR 6-0HDA TREATED MICE 
DAYS AFTER PERCENT OF POPULATION 
INTRAc;EREBRAL SHOWING THE RESPONSE 
INJECTION GROUP +1 +2 +3 
4 Vehicle 100 0 0 
5,6-0HT b) 83 17 0 
6-0HDA . a) 0 8 92 
10 Vehicle 75 25 0 
5,6-0HT b) 42 33 25 
6-0HDA a) 0 0 100 
20 Vehicle 67 33 0 
5,6-0HT b) 42 42 17 
6-0HDA a) 0 0 100 
The percentages (rounded off to the nearest whole 
number) represent the number of animals meeting the crite-
ria described in the methods. N=24 for each group. The 
differences between test scores of 6-0HDA and 5,6-0HT 
treated mice and their controls were evaluated for statis-
tical significance by the Chi-squared statistic. a) In 
the case of 6-0HDA treated mice the null hypothesis was 
rejected for the fourth (p < 0.0005, d. f. = 2, x 2 = 48), 
tenth (p ( 0.0005, d.f. = 2, x 2 = 23), and twentieth (p< 
0.0005, d.f. = 2, x 2 = 23) day after intracerebral injec-
tion. b) In the case of 5,6-0HT treated mice the null 
hypothesis was accepted for the fourth (p < 0. 2, d. f. = 2, 
x 2 = 4.4), tenth (p (0.2, d.f. = 2, x 2 = 4.3) and twen-
tieth (p .£, 0. 2, d. f. = x 2 = 2. 3) day after intracerebral 
injection. 
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While there was a mild increase of the irritability follow-
ing L-DOPA administration in 5,6-0HT treated animals, only 
on the lOth and 20th day following such treatment was a 3+ 
response noticed in a small, 17 to 25%, segment of the pop-
ulation; however, the differences between the L-DOPA re-
sponses of the 5,6-0HT and the vehicle treated animals were 
not statistically significant (Table 5). Thus, 6-0HDA 
treatment, but not vehicle or 5,6-0HT treatment induced a 
significant supersensitive response to L-DOPA. This sug-
gests that a greater change in the catecholaminergic system 
was induced by 6-0HDA than by 5,6-0HT treatment. 
EVERETT TEST AFTER DECARBOXYLASE INHIBITION 
RO 4-4602, an aromatic amino acid decarboxylase in-
hibitor (Pletscher and Bartholini, 1971) interfered with 
the response of the 6-0HDA treated mice to L-DOPA as evalu-
ated by the Everett test (Table 6) • The response was block-
ed by RO 4-4602 at the En50 dose of 70 (95% confidence 
limits 42-117) mg/kg; at this dose, 50% of animals showed 
only a 1+ or 2+ response to L-DOPA. A 25 mg/kg, i.p., dose 
of RO 4-4602, which presumably blocked only peripheral 
decarboxylase and not central decarboxylase, did not inhibit 
the response to L-DOPA of 6-0HDA treated mice. 
TABLE 6. 
EVERETT TEST SCORES OF 6-0HDA TREATED MICE AFTER L-DO~A 
AND VARIOUS DOSES OF R04-·4602 
DOSE OF R04-4602 % OF ANIMALS SHOWING SCORES 
IN MG/KG +3 +2 +1 (n) 
0 75% 8% 17% 12 
25 100% 0% 0% 12 
50 41% 41% 17% 12 
100 55% 36% 9% 11 
200 10% 72% 18% 11 
400 16% 50% 34% 12 
800 0% 64% 36% 11 
OF 
Seventy micrograms of 6-0HDA were given intracerebrally to all 
mice 45 days prior to L-DOPA. R04-4602/l was administered intraperitoneally 
30 minutes prior to L-DOPA. L-DOPA (100 mg/kg) was administered intraperi-
toneally and observations were made 30 minutes later. The Eo50 and 95% con-
fidence limits for blockade of the +3 response by R04-4602 was 70 (42-117) 
mg/kg. 
1-' 
0 
0'1 
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RESPONSE TO APOMORPHINE 
A supersensitive response to apomorphine consisting 
of spontaneous jumping behavior and/or hyperreactivity (cf. 
Methods) was induced in a large percentage of mice treated 
with 6-0HDA; this supersensitivity was observed on all 3 
days of testing (Table 7) • The observed differences be-
tween the number of 6-0HDA treated and vehicle treated mice 
exhibiting supersensitivity (hyperactivity and spontaneous 
jumping, cf. Methods) were statistically signif~cant on the 
4th (p '0. 01) , lOth (p<O. 0005) , and 20th days (p < 0. 01) 
following intracerebral injection (Chi squared statistic) • 
The administration of apomorphine resulted, particularly in 
the case of 6-0HDA pretreated mice in spontaneous jumping 
and hyperactivity ( the mice exhibited jumping and kicking 
on introduction of a foreign object) . Other signs observed 
in mice after apomorphine included a rigid gait, mouthing 
of sawdust, and stereotypic climbing on the wire top of 
the cage (cf. Methods). 
The 5,6-0HT pretreated animals also showed a super-
sensitive response to apomorphine. However, fewer 5,6-0HT 
than 6-0HDA treated mice exhibited spontaneous jumping be-
havior following apomorphine. The differences between the 
number of vehicle and treated mice exhibiting the super-
sensitivity was significant in the case of 5,6-0HT treated 
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TABLE 7 
RESPONSE TO APOMORPHINE IN 5,6-0HT OR 6-0HDA TREATED MICE 
DAYS AFTER 
INTRACEREBRAL 
INJECTION 
4 
10 
20 
GROUP 
Vehicle 
5,6-0HT 
6-0HDA 
Vehicle 
5,6-0HT 
6-0HDA 
Vehicle 
5,6-0HT 
6-0HDA 
a) 
b) 
a) 
b) 
a) 
b) 
PERCENT OF GROUP EXHIBITING 
SUPERSENSITIVITY AS *: 
SPONTANEOUS HYPER-
JUMPING REACTIVITY 
0 16 
41 26 
45 28 
0 8 
33 42 
91 0 
0 16 
33 17 
55 35 
* The remaining mice did not exhibit a supersensitive re-
sponse to apomorphine. 
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LEGEND FOR TABLE 7. 
The table shows the proportion (in percent) of mice 
exhibiting either jumping and hyper.re.activity, or only 
hyperreactivity at various days following the vehicle, 
6-0HD.A or 5, 6-0HT treatment. Twe~ve mice were employed 
in each test. 
The differences between the numbers of mice exhibit-
ing supersensitivity (hyperreactivity alone or jumping as 
well as hyperreactivity) to apomorphine af.te.r 5, 6-0HT or 
6-0HD.A and vehicle treatment were evaluated for statistical 
significance by the Chi-squared statistic. a) The null 
hypothesis that .the differences following 5,6-0HT were due 
to chance was rej.ec.ted for the 4th (pL0.025, d.f. = 1, 
x2 = 6.2) and lOth (p~O.OOl, d.f. = 1, x 2 = 11.0) days 
but accepted for the 20th day (p ::> 0 .1, d. f. = 1, x2 = 3. 0) 
after intracerebral injection. b) The. nul~ hypothesis 
that the observed differences following. 6-0HDA were due to 
chance was rejected for the 4th (pL.O.Ol, d.f. = 1, x 2 = 
7.3} lOth (pL.O.OOOS,. d.f. = 1, x2 = 15-.7) and. 20.th days 
~LO.Ol, d.f. = 1, x 2 = 7.3). 
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animals on the 4th (p (. 0. 025) and lOth (p-< 0. 001) days but 
not on the 20th day. The percentages of responding animals 
were always greater in the case of 6-0HDA than in that of 
5,6-0HT treated mice. 
RESPONSE TO TREMORINE 
A tremorigenic response was present after tremorine 
(10 mg/kg, i.p.) in vehicle treated mice (Table 8). The 
peak tremor response was-observed at 15 minutes after in-
jection. There were no significant differences among the 
mean tremor responses observed in the vehicle treated mice 
on any of the 3 days tested. 
On the 4th day after intracerebral injection of 
6-0HDA the tremorigenic response to tremorine was signifi-
cantly increased. As in the case of the vehicle treated 
mice the peak tremor response in the 6-0HDA treated mice 
occurred 15 minutes after tremorine administration. How-
ever, this increased response to tremorine was not observed 
on the lOth and 20th days after 6-0HDA treatment (Table 8) • 
The peak tremor response was induced by tremorine 15 
minutes after its administration to the 5,6-0HT treated 
mice as was the case with vehicle or 6-0HDA treated mice. 
Similar to the 6-0HDA treated mice, the 5,6-0HT treated 
mice exhibited an enhanced tremor response to tremorine on 
DAYS AFTER 
INTRACEREBRAL 
INJECTION 
4 
10 
20 
TABLE 8. 
TREMORIGENIC RESPONSE TO TREMORINE 
AVERAGE NUMBER OF INTEGRATOR 
GROUP RESETS PER MINUTE + S.E. 
Vehicle 8.64 + 3.73 (9) 
6-0HDA 21.25 + 8.90 (4) (a) 
5,6-0HT 26.24 + 8.93 (5) (b) 
Vehicle 6.66 + 1.12 (17) 
6-0HDA 6.98 + 4.58 (4) 
5,6-0HT 9.89 + 2.73 (13) 
Vehicle 7.82 + 1.96 (17) 
-6-0HDA 6.80 + 1.49 (8) 
5,6-0HT 13.38 + 3.09 (9) (a) 
P VALUE 
< 0.05 
< 0. 025 
N.S. 
N.S. 
N.S. 
.( 0.05 
The average number of integrator resets per minute was cal-
culated for each group 15 minutes after tremorine (10 mg/kg, i.p.). Sta-
tistical significance was determined by the Mann Whitney U test. N.S. 
means not significant. 
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the 4th day after intracerebral injection (p <. 0. 025). · How-
ever, unlike the 6-0HDA treated mice, the 5,6-0HT treated 
mice also exhibited an enhanced tremor response on the 20th 
day following intracerebral injection (p < 0. 05) • On the 
lOth day after injection, the 5,6-0HT also exhibited an 
apparent enhanced tremor response to tremorine, but this 
response was not great enough to be statistically signifi-
cant. Thus, 6-0HDA and 5,6-0HT treated mice were similar 
in their response to tremorine only on the 4th day after 
intracerebral injection, whereas 5,6-0HT treatment appeared 
to induce a longer lasting enhancement of the tremor re-
sponse to tremorine than did 6-0HDA treatment. The onset 
of tremors was not significantly changed in any of the 
groups on any of ·the days tested. 
RESPONSE TO L-5-HTP 
L-5-HTP, 200 mg/kg, i.p., induced a verJ mild tremori-
genic effect in vehicle treated animals. The effect was 
relatively stable with no clear peak effect. In contrast, 
mice which received an intracerebral injection of 6-0HDA 
exhibited a greatly enhanced tremorigenic response to 5-HTP 
(Table 9) on the 4th (p <.0.05), lOth (p ~ 0.01) and 20th 
(p < 0. 005) days after 6-0HDA treatment. Only on the 4th 
post-treatment day was the onset of tremors in 6-0HDA 
TABLE 9 
TREMORIGENIC RESPONSE TO 5-HTP 
DAYS AFTER MINUTES 
INTRACEREBRAL AFTER AVERAGE NUMBER OF INTEGRATOR 
INJECTION L-5-HTP GROUP RESETS PER MINUTE + S. E. P VALUE 
4 30 Vehicle 12.2 + 4.72 (10) 
6-0HDA 18.2 + 2.79 (5) ~ 0.05 
5 Vehicle 3.38 + 1.74 (5) 
5,6-0HT 11.36 + 2.76 (5) .{.. 0.05 
10 30 Vehicle 4.97 + 2.09 (6) 
6-0HDA 28.17 + 7.45 (3) .( 0.01 
Vehicle 2.92 (8) ~ 5 + 0.96 ~ 
5,6-0HT 39.64 + 18.72 (4) .( 0. 025 w 
20 30 Vehicle 4.91 + 1.66 {9) 
6-0HDA 18.53 + 3.05 (3) < 0. 005 
5 Vehicle 4.49 + 1.39 {11) 
5,6-0HT 22.11 + 6.39 (7) < 0. 025 
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· LEGEND: F"OR TABLE :g • 
Tremorigenic response to L-5-HTP .(200 ~g/kg, i.p.) 
was quantified for mice on various days -after the intra-
ceJ;ebral injection of. vehicle, 6-0HDA or 5·,6-0HT. The peak 
res.ponse in 6-0HDA treated mice occurred 30 minutes after 
5-HTJ?, while that of 5,6-0HT treated mice occurred: 5 
minutes after 5-HTP. Significance of. dif.ferences was de-
termined by the Mann Whitney u test. 
12 MINUTES AFTER 5- HTP 
ASCORBIC 6-0HDA 5,6-HT 
REC. ••.•.• 1. ·~ ...... • ~~·~···ttlt ... t .. 
I-' 
I-' 
V1 
J)~~~\J ' ' I ~ \\ \' ~\ I I '. \ . INTG. \___._ '\.~ \~ \lJ ~ \ ' '-----· 
Fig. 7 
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LEGEND FOR FIGURE 7. 
The upper tracing illustrates the unintegrated 
recording of tremor activity in treated mice fifteen 
minutes after L-5-HTP administration on the fourth day 
after intracerebral injection of vehicle, 6-0HDA or 
5,6-0HT (REC). The lower tracings represent the in-
tegrated activity (INTG.) of the upper tracing which 
was used in quantifying the data. Significance of 
differences were based upon the mean number of integra-
tor resets per minute determined for selected five 
minute periods. Ten seconds of recording are illustrated. 
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treated mice significantly more rapid than the onset in the 
vehicle treated mice (1.6 minutes versus 4.1 minutes, 
p<0.05). The peak tremor response in 6-0HDA treated mice 
occurred 30 minutes after L-5-HTP. 
5,6-0HT treatment also markedly increased the re-
sponse to L-5-HTP on the 4th (p < 0. 05) , lOth (p <. 0. 025) and 
20th days (p <. 0. 025). The onset of tremors was more rapid 
only on the 4th day after 5,6-0HT treatment (2.1 minutes 
versus 4 .1 minutes for controls, p <. 0. 0 5) • Thus, mice 
which were treated with either 6-0HDA or 5,6-0HT exhibited 
a marked potentiation of the tremorigenic effect of L-5-HTP 
on each of the days tested; in this case, the two neurotoxins 
were indistinguishable at the doses employed. Figure 7 il-
lustrates the actual recordings of the tremor responses to 
5-HTP obtained in a typical experiment. 
RESPONSE OF 5,6-0HT TREATED MICE TO L-5-HTP AFTER DECAR-
BOXYLASE INHIBITION 
The decarboxylase inhibitor affected in a biphasic 
fashion the response to 5-HTP challenge of mice pretreated 
with 5,6-0HT. At the dose of 25 mg/kg, RO 4-4602 increased 
significantly (p<.0.05) the incidence of intermittent trem-
or (Table 10) and spread eagle response in the 5,6-0HT 
treated animals as compared to vehicle treated mice or mice 
treated with the vehicle and RO 4-4602; at the dose of 
DOSE OF 
R04-4602 
IN MG/KG 
0 
0 
25 
25 
800 
800 
TABLE 10. 
servations 
~~MPTOMOLOG~ IN 5,6-0HT TREATED MICE AFTER L-5HTP AND 
VARIOUS DOSES OF R04-4602/l 
FLUSHED 
EARS AND INTERMITTANT SPREAD 
GROUP PAWS HEAD SHAKING TREMORS EAGLE 
ASC 7/7 6/7 2/7 0/7 
5,6-0HT 6/6 6/6 3/6 3/6 
ASC 0/6 0/6 0/6 0/6 
5,6-0HT 0/6 6/6 6/6 0/6 
ASC 0/4 0/4 0/4 0/4 
5,6-0HT 0/6 0/6 0/6 0/6 
All mice received R04-4602/l 30 minutes before L-5HTP. 
DEATH 
0/7 
3/6 
0/6 
0/6 
0/4 
0/6 
Ob-
were made for one hour following L-5HTP. R04-4602/l was adminis-
tered i.p. All ~ice received 43 Agm/10 ~1 of 5,6-dihydroxytryptamine (5,6-0HT) 
or 10 ul of a l:lOOO.aqueous ascorbic acid vehicle (ASC) 45 days prior to 
L-5HTP (200 mg/kg, i.p.). 
I-' 
I-' 
00 
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800 mg/kg, RO 4-4602 decre·ased significantly (p.(. 0.005} 
the incidence of these responses as well as of the head 
shaking response. On the other hand, at both 25 and 800 
mg/kg dose, RO 4-4602 blocked completely the appearance of 
the peripheral response to 5-HTP, the flush of ears and 
paws, in both vehicle and 5,6-0HT treated mice. 
DISCUSSION 
NEUROCHEMICAL FINDINGS WITH 6-0HDA 
This study compares the effects of two neurotoxic com-
pounds, 5,6-0HT and 6-0HDA, for their selectivity of action. 
Selectivity was assessed by measuring the brain contents of 
four neurotransmitters: DA, NE, 5-HT and ACh. Furthermore, 
the permanence of the neurotoxic sequelae were also evalu-
ated in terms of pharmacological and behavioral responses of 
5,6-0HT and 6-0HDA treated animals to challenges with appro-
priate drugs and precursors. 
As a catecholamine congener, 6-0HDA might be expected 
to affect brain catecholamines to a greater extent than 
brain indolamines (Malmfors and Thoenen, 1971) . In fact, 
it was observed that 6-0HDA was taken up more selectively by 
catecholaminergic rather than indolaminergic terminals of 
the rat brain (Heikkela and Cohen, 1973). Thus, it was ex-
pected that the uptake of 6-0HDA by catecholaminergic neu-
rons would result in their selective destruction as de- · 
scribed by Javoy et al. (1976). The marked declines in the 
brain contents of NE and DA after 6-0HDA indicated that 
a lesion of catecholamine neurons occurred (cf. Table 1). 
It was reported that very similar catecholamine depletion 
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occurred after 6-0HDA in the rat (Breese and Traylor, 1970). 
Aromatic amino acid decarboxylase is an enzyme which 
can synthesize dopamine from L-DOPA (Levine and Sjoerdsma, 
1964) • Our data indicate that the activity of aromatic 
amino acid decarboxylase is not significantly reduced by 
6-0HDA because even after 6-0HDA the brain content of DA can 
I 
still be elevated by L-DOPA (Table 3). Similarly, 6-0HDA 
treatment did not affect the decarboxylation of L-5-HTP to 
5-HT (Table 3) • Similar results were also reported in rats 
treated with 6-0HDA (Urets~y and Schoenfeld, 1971). 
However, there occurred after 6-0HDA (70 Agm/10 ~1) 
treatment a significant reduction in the brain content of 
5-HT. The reduction in 5-HT content was still evident at 
20 days post treatment. This indicates a non selective 
action for 6-0HDA. Thus, it appears that the present method 
cannot be utilized in mice to achieve a total selective le-
sion of central catecholaminergic neurons. The decrease in 
the brain 5-HT content has been previously reported by some 
(Bloom et al., 1969) and denied by other investigators 
{Uretsky and Iversen, 1970~ Jacks et al., 1972). According 
to our data 6-0HDA was only relatively selective at the dose 
employed in the mouse as it induced a greater depletion of 
DA and NE than of 5-HT. It must be emphasized that most in-
vestigators measured 5-HT at 21 days or later, after 6-0HDA 
administration and may have missed earlier unselective ef-
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fects of 6-0HDA on brain 5-HT levels (Bloom et al., 1969; 
uretsky and Iversen, 1970). 
Altogether, our data suggest that 6-0HDA is not taken 
up selectively by catecholaminergic neurons as indicated 
also by neurochemical and histochemical evidence (Fuxe and 
Ungerstedt, 1968; Fozard and Clarke, 1970; Iversen, 1970). 
At the dose of 6-0HDA employed, 6-0HDA appeared to be only 
relatively sel~ctive in its action in the mouse; alterna-
tively, a functional change may have occurred in the sero-
tonergic system following 6-0HDA treatment and this may have 
resulted in the decreased 5-HT levels. 
NEUROCHEMICAL FINDINGS WITH 5,6-0HT 
At the intracerebral dose employed, 43 ~gm/10 /;(. 1, 
5,6-0HT induced marked (up to 53%) and prolonged diminution 
of mouse brain levels of 5-HT. This effect was comparable 
to that obtained by others (Bjorklund et al., 19741 Saner et 
al., 1974). The action was not entirely specific as NE and 
DA levels were also significantly diminished; however, the 
action of 5,6-0HT on catecholamines was less pronounced and 
brief compared to its action on 5-HT. Longo et al. (1974) 
who used doses essentially identical with ours reported ef-
fects of 5,6-0HT on DA content similar to those obtained by 
us; on the other hand, the changes in NE content which they 
12J 
reported were variable. Changes in brain DA and/or NE con-
tent were also obtained by Bjorklund et al. (1974) with 
intraventricular administration and by Breese et al. (1974b) 
with intracisternal administration of 5,6-0HT. Also, Saner 
et al. (1974) who injected 5,6-0HT into median forebrain 
bundle noticed a considerable decrease in DA of the rat 
telencephalon; a similar lack of specificity of 5,6-0HT was 
reported by Baumgarten et al. (1972~,1973). 
It should be emphasized that the depletions of NE and 
DA which were observed in this study after 5,6-0HT were of a 
transient nature since the brain content of these catechola-
mines was not significantly different from that of the 
vehicle treated mice on the lOth and 20th days after 5,6-0HT 
treatment (Table 1). Thus, in our hands 5,6-0HT may have a 
relatively selective effect on the serotonergic system in 
the mouse, as the catecholamines recovered from their ini-
tial depletion while the 5-HT content remained depleted. 
Furthermore, 5,6-0HT treatment did not inhibit the capacity 
of the brain to synthesize catecholamines and serotonin from 
systemically administered L-DOPA and L-5-HTP, respectively 
(Table 3). Finally, 5,6-0HT treatment did not alter the 
resting level of ACh in mouse brain at any time tested. 
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INTERACTIONS BETWEEN THE DOPAMINE'RG'IC , 
CHOLINERGIC AND SEROTONERG'IC SYSTEMS. 
The ability of anticholinergic agents to reverse the 
tremor and rigidity of Parkinsonian patients is well known. 
Also well recognized is the effectiveness of anticholinergic 
agents in the treatment for drug induced extrapyramidal re-
actions. However, the role of dopamine in these conditions 
was not emphasized until the pathological and neurochemical 
etiology of Parkinson's Disease was identified as a de-
ficiency of striatal dopamine (Hornykiewicz, 1966, 1973). 
As a consequence of th{s discovery an interrelationship be-
tween striatal cholinergic and dopaminergic systems was en-
visioned and extensively studied. The resultant experimen-
tation has generally supported such an interrelationship. 
The following discussion will first indicate those experi-
ments which support the concept of a dopaminergic choliner-
gic interaction; second, it will indicate recent findings 
with 6-0HDA which are quite unexpected and which may require 
a slight revision of the concept. 
Several investigations suggest that nigral dopaminer-
gic neurons exert a tonic inhibitory effect on striatal 
cholinergic neurons. For example, Sethy and Van Woert 
(1974 a, b) reported that dopamine receptor stimulation with 
dopamimetics diminishes ACh release and increases striatal 
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ACh content. Conversely, they reported that dopamine re-
ceptor blockers increase ACh release and decrease striatal 
ACh content. Similar findings were reported by Consolo et 
al. (1974b). Furthermore, dopamimetics reduce ACh turnover 
in striatum (Trabucchi et al., 1975a). In contrast, DAre-
ceptor blockers increase striatal ACh turnover (Trabucchi et 
al., 1974). Nigral stimulation induces a release of DA in 
the striatum (Portig and Vogt, 1969) as well as inhibits 
unit activity in the caudate (Connor, 1970; Krnjevic, 1975). 
Moreover, transection of the nigrostriatal pathway dimin-
ishes DA release from the ventricular area of the caudate 
nucleus (Besson et al., 1974). Thus, if the nigrostriatal 
dopaminergic system exerts a physiological tonic inhibition 
of striatal cholinergic cells, it may be expected that 
diminution of the presynaptic supply of DA should result in 
enhanced cholinergic function in the striatum. Inhibition 
of dopamine synthesis by means of ~-mpt, or nerve terminal 
destruction by means of 6-0HDA or lesions of the nigro-
striatal pathway were used to decrease the presynaptic DA 
content; the results of these studies are discussed below. 
Surprisingly, the literature which describes the ef-
fects of ~-mpt, nigrostriatal pathway lesions, or 6-0HDA 
treatment on striatal cholinergic function remains contro-
versial. For example, Beani and Bianchi (1973) reported the 
expected increase in striatal ACh after o(-mpt treatment. 
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gowever, two other groups found Dl-mpt to be without 
effect on striatal ACh levels (Jones et al., 1973; Guyenet 
et al., 1975a). 
The effect of nigrostriatal pathway lesions on stria-
tal function also is surprising. Such lesions did not alter 
the activity of choline acetyltransferease or acetylcholi-
nesterase in the brains of either rats (Me Geer et al., 
1973) or baboons (Katoaka et al., 1974). 
Furthermore, most investigations which employed 6-0HDA 
to diminish the presynaptic supply of DA, found 6-0HDA to be 
without effect on striatal cholinergic function. For in-
stance, Consolo et al. (1974a) found that 6-0HDA did not af-
fect either ACh levels or choline acetyltransferase activity 
of rat striatum. Similar results were obtained by Grewal et 
al. (1974). Furthermore, 6-0HDA treatment did not alter the 
choline acetyltransferase activity of either rat striatum 
(Kim, 1973), substantia nigra (Me Geer et al., 1973) or 
mouse cortex (Kostrzewa, 1973). Kim's (1973} findings did 
not agree with the others since he reported after 6-0HDA a 
marked elevation of rat striatal ACh as well as a decrease 
in acetylcholinesterase activity in rat striatum; however, 
Kim's report (1973} was not confirmed by others. 
It is also interesting to note that 6-0HDA treatment 
did not enhance the increase in striatal ACh utilization 
induced by dopamine receptor antagonists (Stadler et al., 
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1973). Conversely, 6-0HDA treatment did not antagonize the 
diminution of ACh utilization induced by dopamine receptor 
agonists (Ladinsky et al., 1975). Lastly, and even more 
surprising is the fact that the inhibitory effect of nigral 
stimulation is not inhibited by 6-0HDA treatment (Krnjevic, 
19 7 4) • 
In summary, directly acting DA receptor agonists have 
consistent effects on striatal ACh; the effects of indirect-
ly acting DA receptor agonists on striatal ACh remain con-
troversial. Thus, it appears that not all problems have 
been resolved in establishing a concept of a physiological, 
dopaminergic,tonic inhibition of striatal cholinergic cells. 
Since the ·brain part that we analyzed contained the 
striatum, our data have relevance to the concept of a stria-
tal dopaminergic cholinergic interaction. Basically, nei-
ther 6-0HDA nor 5,6-0HT changed endogenous ACh levels (Table 
2). The data with 6-0HDA are in direct agreement with those 
of Jacks et al. (1972) and Consolo et al. (1974a). The data 
with 5,6-0HT are novel. Our data with 6-0HDA contributes to 
a growing body of evidence which suggests that 6-0HDA treat-
ment is without effect on striatal ACh levels. 
Furthermore, our own data and those of others (cf. 
above) suggest that excessive DA receptor stimulation rather 
than tonic DA receptor stimulation inhibits striatal ACh 
utilization. This latter statement may be supported by the 
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results of Agid et al. (1975) who demonstrated again that 
6-0HDA alone did not reduce striatal ACh levels; however, 
6-0HDA did inhibit the increase in striatal ACh levels in-
duced by a high dose (10 mg/kg) of amphetamine. 
In an attempt to put the 6-0HDA data in line with the 
hypothesis of a tonic inhibitory action of DA on striatal 
ACh cells the following hypotheses may be considered. It 
may be argued that we did not achieve sufficient depletion 
of DA to modify cholinergic function. However, Guynet et 
al. (1975a) achieved after 6-0HDA a DA level of only 5% of 
normal, without being able to detect alterations in ACh con-
tent. It may also be argued that the dopaminoceptive cho-
linergic neurons may only be a small percentage of the total 
population of cholinergic neurons in striatum. Alternative-
ly, it may also be argued that after 6-0HDA a quasi-normal 
state of cholinergic function could be maintained by super-
sensitive DA receptors. Obviously, further studies of the 
interaction of the dopaminergic system on the cholinergic 
system with respect to both levels and turnover values of 
acetylcholine, after presynaptic alterations of the nigra-
striatal pathway (Costa and Neff, 1968) ,are needed for the 
resolution of this important point. 
Also related to this matter of a dopaminergic choli-
nergic interaction are our results following L-DOPA treat-
ment. Our results indicate that L-DOPA administration to 
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either vehicle, 6-0HDA or 5,6-0HT treated animals, and the 
resultant increase in the level of DA, did not affect brain 
ACh levels. Similarly, Sethy and Van Woert (1973) found no 
change in rat brain ACh levels with a single administration 
of L-DOPA but a small (8-13%) increase in ACh content was 
observed with chronic L-DOPA. The lack of effect of L-DOPA 
on neostriata! levels of ACh was also reported by others 
(Beani et al., 1966~ Beani and Bianchi, 1973). It was re-
cently reported that a decarboxylase inhibitor may be nec-
essary to demonstrate acute effects of L-DOPA on the stria-
tal cholinergic neurons (Sethy and Van Woert, 1974 a, b). 
This later result appears to be a sufficient explanation of 
the present results. In summary, since 6-0HDA did not reduce 
brain ACh content, we may conclude that 6-0HDA did not 
destroy central cholinergic neurons. The results of others 
(cf. above) also lead to a similar conclusion. 
However, the results obtained with tremorine appear 
inconsistent with respect to this concept. An enhanced re-
sponse to tremorine was observed on the fourth, but not on the 
tenth or twentieth days after 6-0HDA. The enhancement of the re-
sponse to tremorine on the 4th day suggests a supersensitivity 
of cholinergic receptors. At least three other published hy-
potheses may be related to this result. The first is that 
6-0HDA induced a diminution of DA and resulted in a dis-
inhibited cholinergic state (see previous discussion}. 
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The second is that striatal cells become more sensitive to 
ACh or to muscarinic agonists, following the loss of DA as 
suggested by Spehlmann (1975) • The third is that the super-
sensitive response to tremorine was indirect and mediated by. 
the 6-0HDA induced supersensitivity of the catecholaminergic 
system (Tables 4, 5, 7). 
To expand upon and to explain the last hypothesis, sev-
eral studies suggested that the cholinergic system may exert 
its effects by means of the catecholaminergic system. For 
instance, the antirecruitment effects of the anticholines-
terase, physostigmine, requires a non-depleted pool of cate-
cholamines (Van Meter and Karczmar, 1971). Furthermore, in-
creases in ACh levels can induce an increase in DA and a de-
crease in NE levels (Glisson et al., 1972). This latter ef-
fect may occur in the case of both a normal or a particular-
ly increased supply of catecholamines (Glisson et al., 1972, 
1974). Moreover, oxotremorine, a muscarinic agonist, in-
creases striatal DA content (Javoy et al., 1974 a, b). Fi-
nally, the locomotor stimulatory effects of anticholinergic 
compounds, even those which do not block DA uptake (Coyle 
et al., 1969), are dependent upon a presynaptic supply of 
dopamine (Thornburg and Moore, 1973 a, b). 
While any one of these hypotheses may explain the en-
hanced response to tremorine on the 4th day after 6-0HDA, 
they do not explain the lack of an increased response to 
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tremorine on the lOth and 20th days after 6-0HDA. The lat-
ter result may be explained as a long term accommodation of 
cholinergic function which occurs in response to an acute 
6-0HDA induced perturbation of cholinergic function (Agid et 
al., 19 75) • 
In summary, since 6-0HDA treatment did not induce a 
decrease in brain ACh levels nor did it induce a long term 
supersensitivity to tremorine, it may be concluded that 
6-0HDA did not induce a lesion of cholinergic neurons. In-
stead, the transitory increased response to tremorine on the 
4th day may reflect a 6-0HDA induced alteration in neuro-
transmitter system interactions. Obviously, much additional 
research would be required to adequately resolve this com-
plex issue. 
A special consideration should be given to the novel 
results obtained with respect to an interaction between 
5-HT and ACh. While the diminution of 5-HT levels by the 
5,6-0HT treatment did not affect ACh levels, the latter were 
markedly increased following the 5-HTP challenge of the con-
trol and 6-0HDA treated mice. However, the 5-HTP challenge 
did not increase the levels of ACh in the 5,6-0HT pretreated 
mice. The results indicate that 5-HTP may increase the ACh 
levels only in the presence of relatively intact serotoner-
gic neurons as in the case of the ascorbic acid or the 6-
0HDA treated animals. Somewhat similar conclusions were 
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reached by Pepeu et al.(l974a) who demonstrated an increase 
in ACh release after a 5-HTP administration to parachlor-
phenylalanine treated rats, but not in rats with lesions of 
the raphe nuclei. 
A serotonergic-cholinergic interaction has also been 
suggested by the observation of parallel decreases in both 
ACh and 5-HT levels in animals with septal lesions (Heller 
et al., 1962). Recently, Barnes et al. (1974) have shown 
that central accumulation of ACh leads to marked increases 
of 5-HT in several brain parts. The data of Haubrich and 
Reid (1972) also support the concept of a serotonergic-
cholinergic interaction as they reported an increase in 5-HT 
turnover following muscarinic agonists. Furthermore, the 
serotonomimetic agent, quipazine, raises striatal ACh lev-
els; this effect is considered to be mediated through the 
serotonergic system (Euvrard et al.,l977). Harmaline,a mono-
mine oxidase inhibitor of indole derivation, increases 
striatal ACh levels. The effect is not mediated by an in-
teraction with the dopaminergic or gabaminergic systems. It 
also appears that the effect of harmaline may not be medi-
ated through the serotonergic system (Javoy et al., 1977). 
T~us, although evidence is accumulating for a serotonergic-
cholinergic interaction there may be even other neurotrans-
mitter cholinergic interactions in striatum which are still 
to be identified. Altogether, the data of others as well as 
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our own suggest that the serotonergic and cholinergic 
systems may affect each other's function. 
Evidence exists which suggests that the dopaminergic 
and serotonergic systems also interact. L-DOPA has been 
shown to cause a reduction in brain 5-HT content (Everett 
et al., 1970; Bartholini et al., 1968; Butcher et al., 
1969). A serotonin depleting effect of L-DOPA was also 
observed in this study (Table 3). Moreover, this effect of 
L-DOPA on brain 5-HT is attenuated by 6-0HDA treatment as 
shown by Algeri et al. (1974) and as observed in this study 
as well (Table 3) • The L-DOPA induced inhibition of spon-
taneous motor activity and the hypothermia were attributed 
to the release of cerebral 5-HT stores (Maj et al., 1971, 
1973, 1974). Furthermore, 6-0HDA and oL-mpt (Jouvet et al., 
1973) were shown to increase 5-HT turnover in brain. 
Some data also indicate that L-DOPA-serotonin inter-
action exists in man as the lumbar cerebrospinal fluid 
levels of 5-HIAA were elevated following L-DOPA treatment 
(Chase, 1974). In fact, an inverse correlation exists be-
tween the degree of akinesia and rigidity in Parkinsonism 
and the degree of 5-HT depletion (Chase, 1974). However, 
the addition of PCPA to L-DOPA treatment of Parkinsonism did 
not affect the therapeutic efficacy (Chase, 1974). More re-
cently, apomorphine was reported to increase the turnover of 
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orain 5-HT (Grabowska, 1974). To the contrary, another 
dopaminergic agonist, ET 495, was without affect on the rat 
brain levels of 5-HT or 5HIAA (Consolo et al., 1975). These 
findings merely illustrate the complexity of interpretation 
of neurotransmitter interactions and the need for additional 
research to identify functional relationships between these 
neurotransmitter systems. In summary our data support the 
reported L-DOPA induced depletion of 5-HT and also confirms 
the reported impairment of this effect by 6-0HDA treatment. 
PHARMACOLOGICAL AND BEHAVIORAL RESULTS AND THEIR RELA-
TIONSHIP TO THE 5-HT, ACh AND CATECHOLAMINE SYSTEMS 
RELEVANCE OF THE EFFECTS OF 6-0HDA AND 5,6-0HT ON LOCO-
MOTOR ACTIVITY TO THE FUNCTIONAL STATE OF BIOAMINE SYSTEMS 
While the opinion was not unanimous, 6-0HDA was re-
ported to cause behavioral and locomotor depression (Cooper 
et al., 1973) as it did in this study. There were relative-
ly few studies of the locomotor effects of 5,6-0HT; the 
results of Longo et al. (1974) and the present as well as 
our earlier data (Barnes et al., 1973 a, c» indicate that 
this compound markedly decreased motor activity, contrary to 
the non-quantified data of Baumgarten et al. (1972b), Da 
Prada (1972) and Longo et al. (1974). On the other hand, 
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disinhibitory or excitatory effects of 5,6-0HT were more in 
keeping with the opinion held by many since the early sug-
gestion of Brodie and Shore (1957) that 5-HT was a behavior-
al suppressant; indeed, some of our own data {cf. below) may 
be consistent with this concept. 
The 5,6-0HT treated animals while exhibiting initially 
a depression of locomotor activity, showed subsequently some 
recovery in the continuous test paradigm as their locomotor 
activity was no longer significantly depressed, compared to 
the controls, after the fifth post-treatment day (Figure 3). 
On the other hand, when the single test procedure was em-
ployed the motor activity of the 5,6-0HT treated group re-
mained depressed through the tenth post-treatment day 
(Figure 2) • The apparent earlier recovery of motor activ-
ity in 5,6-0HT treated mice in the repeated test may be ex-
plained as follows. The vehicle treated animals show habit-
uation to the cage and exhibit, in repeated tests, a pro-
gressive reduction in locomotor activity~ this habituation 
may not have occurred in the 5,6-0HT treated mice. Indeed, 
the locomotor activity of the vehicle treated mice progres-
sively decreased and by the 5th day approached the level ex-
hibited by the 5,6-0HT treated mice. The 5,6-0HT treated 
mice eventually did exhibit habituation but only after the 
11th day; interestingly, exploratory activity returned to 
normal at this time in the single test procedure. Thus, the 
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data suggest that a return of the habituation phenomenon in 
mice may reflect in a repeated test design the recovery of 
exploratory motor activity. 
In the 5,6-0HT treated mice the catecholamines were 
at normal levels on the lOth post-treatment day; it may be 
inferred therefore that the occurrence of the habituation 
phenomenon in 5,6-0HT treated mice may be a reflection of 
the recovery of the catecholamines. The lack of dependence 
of the habituation response upon brain catecholamine level 
was implied by the results in the repeated tests with 6-0HDA 
treated mice. The habituation response was observed as 
early as the 5th post-treatment day and continued there-
after inspite of the greater depletion of catecholamines 
in the 6-0HDA treated mice as opposed to the 5,6-0HT treated 
mice. Moreover, recovery of exploratory activity in 6-0HDA 
treated mice also occurred early (on the 4th post-treatment 
day), again inspite of low catecholamine levels. 
Controversy surrounds the mechanism of the locomotor 
depression induced by 6-0HDA or 5,6-0HT. Some have suggest-
ed that the depression of locomotor activity by 6-0HDA was a 
non-specific toxic effect {Taylor et al., 1970; Evetts and 
Iversen, 1970; Scotti de Carolis et al., 1971). There is 
evidence for independence of locomotor depression from the 
catecholamine depleting action of 6-0HDA; for instance, even 
though pretrea~~ent with desipramine prevented the depletion 
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of NE by 6-0HDA, it did not prevent the locomotor depression 
induced by 6-0HDA (Scotti de Carolis et al., 1971). How-
ever, the evidence presented was not completely convincing 
since the levels of NE were determined but not those of DA. 
Moreover, it has been previously reported that NE uptake 
blockers such as protriptyline can spare the noradrenergic 
terminals but not the dopaminergic terminals from destruc-
tion by 6-0HDA (Evetts and Iversen, 1970). Thus, the be-
havioral depressant effects in the absence of NE depletion 
may reflect normal NE levels and depleted DA levels; the 
latter may,per se, depress locomotor behavior. The role of 
catecholamine depletion in the depression of locomotion was 
also suggested by our own 5,6-0HT data, as 5,6-0HT induced 
early catecholamine depletion and depression of locomotion. 
Not only does controversy exist concerning the cause 
of locomotor depression by 6-0HDA or 5,6-0HT but also con-
cerning the nature of the recovery of exploratory locomotor 
behavior. Aside from the suggestion of recovery from non-
specific toxic effects it was suggested that supersensitiv• . 
ity of postsynaptic dopamine receptors may account for the 
recovery of locomotor behavior after 6-0HDA (Ungerstedt, 
197la). Alternatively, it was suggested that other neuro-
transmitter systems may take over the functional role of the 
destroyed systems and thereby maintain behavior (Longo, 
1975) • On the other hand, it is also conceivable that the 
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recovery of spontaneous exploratory locomotion in rodents 
after either 6-0HDA or 5,6-0HT treatments may be due to the 
restoration of a functional catecholamine pool. The latter 
has been suggested as the mechanism for the behavioral re-
covery from 6-0HDA induced anorexia in rats (Zigmond and 
Stricker, 1973). 
Our data are relevant to the nature of the depression 
as well as recovery of locomotor activity after 6-0HDA. The 
data indicate that L-DOPA stimulated the locomotor activity 
of 6-0HDA ~reated mice to a greater degree than that of the 
vehicle treated mice as early as one day after 6-0HDA 
(Figure 6); this was at the time when the spontaneous ex-
ploratory activity of 6-0HDA treated mice was markedly de-
pressed. Similarly, on the 4th and lOth days after 5,6-0HT 
treatment, mice exhibited a supersensitivity to apomorphine; 
on these days they also exhibited a depression of spontane-
ous locomotor activity. Thus, while supersensitivity of DA 
receptors was present it could not account for the recovery 
of spontaneous locomotor activity which occurred several 
days later. As L-DOPA stimulated the locomotor activity of 
6-0HDA treated mice to a greater extent than that of vehicle 
treated mice, it appeared that 6-0HDA did not have a non-
specific toxic effect on the efferent pathways responsible 
for locomotor behavior. A pertinent suggestion was 
that 6-0HDA induced a sensory deficit (Ljungberg and 
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ungerstedt, 1976) • 
As there does not appear to be deficit in the ef-
ferent locomotor pathway (cf. above) and in view of the 
strong implication of the role of catecholamines in loco-
motor beh~vior from previous studies (cf. Introduction), a 
catecholamine hypothesis for the recovery of exploratory be-
havior is still tenable if viewed in the following way. The 
neurotoxins, 6-0HDA and 5,6-0HT, induce a loss of a func-
tional pool of catecholamines. The loss of this functional 
pool may be responsible for the initial depression of loco-
motion observed after each neurotoxin. Furthermore, the re-
covery of the activity of this functional pool may parallel 
the recovery of exploratory behavior and habituation phenom-
enon in mice which received either neurotoxin. The effects 
of the functional pool may be amplified by the existence of 
a concomitant receptor supersensitivity. Thus, our data ap-
pear to be consistent with the concepts of a catecholamine 
involvement with locomotion and with that of a functional 
catecholamine pool. Further experiments are needed to sup-
port these postulated functional relationships involved in 
recovery of locomotion which occurs in spite of prolonged 
catecholamine depletion in 6-0HDA treated mice. 
That the methamphetamine effect was reduced by 6-0HDA 
pretreatment was not surprising, as amphetamines act at 
least in part, via a presynaptic release of NE and DA (Moore 
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et al., 1970; Carlsson, 1970; Costa and Groppeti, 1970), 
and as the stores of NE and DA were diminished in the 6-
0HDA treated mice. There was little or no recovery of this 
effect throughout the test period in both the repeated and 
single test procedure (Figures 4 and 5) , in agreement with 
the prolonged effect of 6-0HDA on brain catecholamines 
(Table 1) • Similar results were obtained by others (Fibiger 
et al., 1973; Creese and Iversen, 1974). 
Soon after 5,6-0HT treatment, mice exhibited a reduced 
response to methamphetamine. This effect was observed in 
the case of the single test procedure on the 1st b~t not on 
the 4th post-treatment day, and through the 7th post-treat-
ment day in the case of the repeated test. In the repeated 
test, the 5,6-0HT treated mice exhibited a trend of a grad-
ually increasing response to methamphetamine after the ini-
tial inhibition observed on the 1st post-treatment day 
(Figure 3). The slow progressive trend may have reflected a 
gradual return of the catecholamines to normal from their 
depleted levels. Normal catecholamine levels were observed 
on the lOth post-treatment day. After the initial dimin-
ished response to methamphetamine on the first day, the 5,6-
0HT treated mice subsequently exhibited in the single test 
procedure an increased locomotor response to methamphetamine 
(Figure 4) • This increased response to methamphetamine in 
5,6-0HT treated animals may have reflected a loss of the in-
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hibitory serotonergic system which was postulated (Baldes-
sarini et al., 1975; Creese and Iversen, 1974; Green and 
Harvey, 1974; Mabry and Campbell, 1973, 1974; Mogilnicka et 
al., 1977) to modulate catecholamine arousal in the rat; al-
though the concept was questioned by Jacobs et al. (1975a) 
it was recently reconfirmed in rats by Breese et al. (1974a) • 
The absence of an enhanced response to methamphetamine in 
6-0HDA treated animals whose 5-HT is depleted may have been 
a result of the persistent marked depletion of NE and DA in 
these mice. Moreover, on the 20th day following 5,6-0HT 
treatment the catecholamines but not 5-HT levels were restored 
and there was an enhanced locomotor response to methampheta-
mine. Thus, the present data support the concept of a sero-
tonergic inhibition of catecholamine mediated locomotion and 
also of the presynaptic, indirect mechanism for the action 
of methamphetamine. 
PHARMACOLOGICAL ASSESSMENT OF CNS FUNCTION AFTER 6-0HDA OR 
5,6-0HT TREATMENT 
It was established that supersensitivity phenomena in 
the periphery are associated with either the denervation or 
disuse of synaptic junctions (cf. Introduction). 6-0HDA and 
5,6-0HT were expected to chemically denervate and induce 
disuse of central catecholaminergic and serotonergic path-
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ways, respectively. Thus, the development of supersensi-
tive responses to central agonists was. considered in this 
study to be indicative of the neuronal destruction induced 
by 6-0HDA and 5,6-0HT. It was expected that lesions of 
serotonergic nerve terminals would induce a supersensitive 
response to L-5-HTP, whereas lesions of dopaminergic nerve 
terminals would induce supersensitive responses to apomor-
phine and L-DOPA. Finally, lesions of cholinergic terminals 
were expec.ted to induce a supersensitive response to the 
centrally acting, cholinergic agonist, tremorine. 
Some properties of supersensitivity phenomena in the 
central nervous system may be expected to resemble these 
phenomena in the periphery. In the case of the loss of 
central presynaptic nerve terminals, which possess active 
high affinity neurotransmitter uptake mechanisms, it would 
be expected that a rather specific supersensitive response 
of the prejunctional type would develop. As in the periph-
ery, the central prejunctional type of supersensitivity 
would be expected to develop soon after the loss of the 
neurotransmitter uptake process. Moreover, a prejunctional 
type of supersensitivity may be expected in the case of. cen-
tral catecholaminergic, serotonergic and cholinergic neurons 
all of which have well documented high affinity uptake 
mechanisms (Iversen and Neal, 1968; Yamamura and Snyder, 
1972). 
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On the other hand, demonstration of the postsynaptic 
type of supersensitivity in the central nervous system poses 
several problems. One problem is whether postsynaptic 
supersensitivity of central receptors will exhibit the same 
characteristics of non-specificity and delayed development 
as exhibited by postjunctional supersensitivity in the pe-
riphery (cf. Introduction}. Indeed, since central neurons 
are sensitive to several neurotransmitters (Yarbrough and 
Phillis, 1975} denervation or disuse of one neurotransmitter 
input to a neuron may result in the development of supersen-
sitivity to all of its other neurotransmitter inputs. In 
contrast, it is conceivable that postsynaptic supersensi-
tivity of central receptors can be very specific in nature. 
This question is difficult to answer because polysynaptic 
pathways are involved in the ultimate expression of be-
havioral responses. Therefore, it is difficult to demon-
strate that supersensitivity of only one neuronal pool is 
responsible for the behavioral expression of supersensitiv-
ity. Indeed, neurotoxin-induced alteration of a single re-
ceptor of a synapse constituting a link in a synaptic chain, 
may initiate secondary changes in the other synaptic junc-
tions of the chain which utilize different neurotransmit-
ters. These secondary compensatory changes may mimic non-
specific supersensitivity of the originally affected synap-
tic junction. 
144 
Other methodological difficulties occur when one con-
siders the possibility of the existence of isoreceptors. 
For example, some investigators have postulated the exist-
ence of several different types of dopamine receptors. DA 
receptors have been characterized as being excitatory or in-
hibitory (Cools and Van Rossum, 1976) as well as presynaptic 
and postsynaptic (Bunney and Aghajanian, 1975). Thus, with 
the possibility of the existence of several receptor sub-
types the interpretation of the behavioral expressions of 
neurotoxin-induced central receptor supersensitivity becomes 
even more complex. The following pages will describe the 
responses of mice to several pharmacological agonists after 
· 6-0HDA and 5,6-0HT treatments and relate them to the develop-
ment of changes in receptor sensitivity. 
CHOLINERGIC SYSTEM 
Originally, it was suggested that the action of trem-
orine was indirect, via a stimulated synthesis and release 
of ACh (Marchbanks, 1969}. This hypothesis may need re-
vision (Cox and Potkonjak, 1969b). Oxotremorine increased 
the brain levels of acetylcholine in the rat (Cox and Pot-
konjak, 1969a) and cat (Pepeu et al., 1968); this is con-
sistent with decreased ACh turnover. In fact, oxotremorine 
decreased ACh turnover (Trabucchi et al., 1975b) and ACh re-
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lease (Szerb and Somogyi, 1973). Furthermore, a causal role 
of increased ACh levels in tremor production following 
tremorine was questioned since anticholinesterase agents 
potentiated the increase in brain ACh but did not potentiate 
the tremor (Cox and Potkonjak, 1969b). Furthermore, drugs 
such as propranolol, reserpine,~-mpt and diethyldithiocar-
bamic acid were capable of inhibiting oxotremorine induced 
tremor while they did not affect the increase in ACh levels 
(Cox and Potkonjak, 1970). On the other hand, tremor in-
duced by oxotremorine is readily blocked by atropine at 
doses which did not prevent the increase in whole brain ACh 
(Cox and Potkonjak, 1969b). These recent data suggest that 
tremorine after conversion to oxotremorine probably induces 
tremor through a direct action on central muscarinic recep-
tors (Cox and Potkonjak, 1969a,b) • 
Tremorine also induces changes in the bioamines. Do-
pamine levels were reported to increase after tremorine in 
the rat, guinea pig and rabbit(Friedman et al.,l967}. Fur-
thermore, brain stem levels of norepinephrine decreased and 
those of serotonin increased (Friedman et al., 1963). Re-
cently, the increase in 5-HT was correlated to the hypother-
mic action of tremorine (Cox and Potkonjak, 1967) ; the 
latter investigators could not find any changes in the brain 
DA content of tremorine treated rats. The decrease in NE 
was substantiated and found to be independent of tremorine's 
hypothermic effect (Cox and Potkonjak, 1967). A muscarinic 
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mechanism was .suggested for the decrease in NE (Cox and 
Potkonjak, 1967) • Some role of NE in tremor production by 
tremorine was implied since NE depleting agents and beta-
adrenergic blocking agents inhibit tremorine tremor (Cox 
and Potkonjak, 1970; Leslie et al., 1972). However, the 
local anesthetic effects of beta-adrenergic blocking agents 
or a non-specific depression of motor function with NE de-
pleting agents may be responsible for the antagonism of 
tremor (Cox and Potkonjak, 1970) . 
The locus of tremor production appears to be with 
the extrapyramidal motor system; the tremor may be initiated 
in the neostriatum. Tremorine and oxotremorine, its active 
metabolite, induce tremor in a cerebellectomized preparation 
(Everett, 1956) and in decerebrate animals (Everett et al., 
1956); mesencephalic tegmental lesions, however, inhibit 
tremor induced by these drugs (Tasker and Kertesz, 1965). 
Moreover, stereotaxic implantation of tremorine into either 
globus pallidus, caudate nucleus and substantia nigra result 
in tremor production (Cox and Potkonjak, 1969a) • Similarly 
intracaudate injections of another muscarinic cholinergic 
agent carbachol also induced tremor (Connor et al., 1966). 
Thus, an intact neostriata! and lower brain stem structures 
are necessary for the expression of tremorine tremor. 
Since 6-0HDA decreased DA and NE, it may be expected 
that this depletion of catecholarnines would inhibit the 
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action of tremorine. A similar inhibition of tremor might 
be expected early after 5,6-0HT treatment when the catecho-
lamines were depleted. These expectations were not realiz-
ed. On the 4th day following either 6-0HDA or 5,6-0HT 
treatment, the tremorine responses were greatly exaggerated 
{Table 8). It should be emphasized that these exaggerated 
responses were obtained in the absence of any significant 
change in ACh levels whether in the 6-0HDA treated or in 
5,6-0HT treated animals. The exaggerated response to trem-
orine appeared to be longer lasting in the case of 5,6-0HT 
treated mice since it was still evident on the 20th post-
treatment day. The particular sensitivity of the 5,6-0HT 
treated animals to tremorine suggests that the phenomenon 
may depend in part on the lesion of the serotonin containing 
neurons, since on the 20th post-treatment day both the 
levels of NE and DA had returned to normal levels and since 
there was no evidence of supersensitivity of catecholamine 
receptors in these mice as evidenced by no enhanced response 
to apomorphine or L-DOPA. Tremorine increased central 
levels of ACh (Holmstedt and Lundgren, 1966); which in turn 
may induce increased 5-HT levels (Barnes et al., 1974) to 
which the 5,6-0HT treated animals were shown to be supersen-
sitive (cf. next section). Altogether, the finding of an 
exaggerated response to tremorine, in spite of lowered brain 
levels of NE and DA in both 5,6-0HT and 6-0HDA treated mice 
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on the 4th day (Table 8) , was surprising in light of the 
expectations. 
It may be suggested that 1) either the serotonergic 
system supersensitivity is involved in the elaboration of 
tremor following tremorine; indeed 5-HT but not NE or DA was 
markedly depleted 20 days following 5,6-0HT treatment and 
at that time the exaggerated response to tremorine was still 
evident; 2) a hitherto undetected change in central choli-· 
nergic function may have occurred following either 6-0HDA 
or 5,6-0HT treatment. 
SEROTONERGIC SYSTEM 
L-5-HTP was used to stimulate postsynaptic serotono-
ceptive receptors and thereby assess their functional state. 
5-HTP and high serum tryptophan levels increase the brain 
content of 5-HT (Bogdanski et al., 1958J Fernstrom and 
Wurtman, 1972); 5-HTP retained this ability after either 
6-0HDA or 5,6-0HT treatment (Table 3). Unfortunately, 5-HTP 
is taken up by the neurons rather unspecifically and it may 
displace endogenous stores of NE (Dahlstrom and Fuxe, 1964; 
Corradi et al., 1967). Tryptophan may be a more selective 
precursor of 5-HT than is 5-HTP; this is evidenced by the 
selective enhancement of the fluorescence of raphe terminals 
{Aghajanian and Asher, 1971) and by increased brain 5-HT 
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after tryptophan loading (Grahme-Smith, 1971). However, 
tryptophan may be inappropriate to test serotonoceptive re-
ceptor function since in the case of 5,6-0HT treatment a de-
crease in tryptophan hydroxylase has been observed and this 
may limit the amount of conversion of L-tryptophan to 5-HT 
(Victor et al., 1973 ; Lovenburg and Victor, 1974). Fur-
thermore, it is not yet clear whether the observed increase 
in brain indole fluorescence following tryptophan is due to 
the accumulation of serotonin or, in addition, to other in-
dolamines (Bjorklund et al., 1971). Anden (1968) suggested 
that 5-HTP stimulates serotonergic receptors as evidenced 
by an enhancement of the hindlimb extensor reflex. In ad-
dition, blockers of 5-HT uptake also enhance the hindlimb 
extensor reflex by enhancing the amount of serotonin at the 
synapse (Meek et al., 1970). The extensor reflex was 
utilized to demonstrate the destruction of serotonergic 
terminals by 5,6-0HT (Daly et al., 1973); a combination of 
drugs requiring the presynaptic integrity of 5-HT terminals 
could no longer exert their influence on the reflex after 
5,6-0HT treatment. 
The tremorigenic response to 5-HTP was greatly in-
creased throughout the testing period of 20 days in the 
5,6-0HT and 6-0HDA treated mice. The results of this inves-
tigation were the first description of central 5-HT receptor 
supersensitivity (Barnes et al., 1973 a, c). The phenomena 
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of central 5-HT receptor supersensitivity has been recently 
confirmed by others (Gerson and Baldessarini, 1975; Jacobs 
et al., 1975b; Klawans et al., 1975; Longo et al., 1974; 
Stewart et al., 1976). The mechanism of this supersensitiv-
ity may be analogous to that hypothesized for the increased 
sensitivity to L-DOPA of 6-0HDA treated animals (Barnes 
et al., 1973b); while the latter may be due to the impair-
ment of NE and/or DA uptake by the catecholamine nerve 
terminals (Bell et al., 1970} or due to changes in post-
synaptic NE and/or DA receptor sensitivities (Ungerstedt, 
197la}, the increased sensitivity to 5-HTP in 5,6-0HT treat-
ed animals may be due to a lesion of the serotonergic neurons 
(Baumgarten et al., 1973). Thus, a lesion of serotonergic 
terminals may result in an impairment of the 5-HT uptake by 
serotonergic neurons and induce a presynaptic type of super-
sensitivity (Daly et al., 1973; cf. Introduction}. There 
may also be an increase in the sensitivity of the post-
synaptic 5-HT receptor. In a similar ve.in, the supersensi-
tivity to 5-HTP observed also in the case of 6-0HDA treated 
animals may be related to a lesion of 5-HT containing 
neurons which may be surmised on the basis of the long last-
ing depletion of 5-HT recorded in these animals (Table 1). 
In fact, the question might be raised as to the signi-
ficance of dopamine or norepinephrine depletion as possible 
mechanisms for the enhancement of the 5-HTP response since 
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these occurred in mice treated with either 6-0HDA or 5,6-
0HT (Table 1). However, a serotonergic involvement can be 
suggested by examination of the tremor responses and neuro-
chemical findings in mice on the 20th day after intracere-
bral injection of 5,6-0HT or 6-0HDA. In the case of 6-0HDA, 
5-HT was still depleted as were the catecholamines. However, 
in the case of 5,6-0HT treated mice only the levels of 5-HT 
but not those of NE and DA were significantly depleted on the 
20th day after intracerebral injection. In fact, in view of 
the results obtained with the DOPA test and apomorphine test 
on the 20th day after 5,6-0HT (cf. next section) it could be 
concluded that supersensitivity of catecholaminoceptive re-
ceptors was not present on that day. Therefore, the en-
hanced response of 5,6-0HT treated mice to 5-HTP was most 
probably related to a destruction of brain serotonergic 
systems, and this mechanism probably accounts for the similar 
findings in 6-0HDA treated mice. 
It would be interesting to examine the possibility 
that 5-HTP induced tremors may be induced by activation of 
the inferior olive cells and the corresponding climbing 
fiber input into the cerebellum (Llinas and Volkind, 1973) 
similar to that induced by harmaline. Such a mechanism 
should help elucidate the 5-HT-DA mechanism involved in 
Parkinsons disease, especially since it has not been possi-
ble to induce a Parkinsonism tremor in primates unless both 
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striatal DA and 5-HT were lowered by a ventrotegmental 
lesion (Poirier and Sourkes, 1976); this has cast some doubt 
as to a purely dopaminergic etiology for the disease. Ad-
mittedly, it is a frequent finding that both DA and 5-HT 
are depleted in the Parkinsonism patient (Hornykiewicz, 1973 
a,b). It has been suggested that tremor results when the 
dopaminergic system is impaired in animals with lesions in 
the rubro-olivo-cerebellar pathway (Larochelle et al., 
1971}. Obviously, additional research is needed to eluci-
date the physiological role of 5-HT and the other neuro-
transmitters in the extrapyramidal motor system. 
CATECHOLAMINERGIC SYSTEM 
The response of the 5,6-0HT treated animals to L-DOPA 
should be compared with those of 6-0HDA treated animals 
(Tables 5 and 7, Figure 6}. Without DOPA treatment neither 
group displayed aggression or hyperirritability as described 
by Nakamura (1972} for 6-0HDA treated rats. In confirmation 
of the data of others (Ungerstedt,l97la; Uretsky and Schoen-
feld, 1971} the 6-0HDA treated animals exhibited in our 
hands an exaggerated response to L-DOPA, whether this re-
sponse was evaluated by the Everett test (Everett, 1962, 
1967} or in terms of changes in the locomotor activity after 
L-DOPA. In sharp contrast, the response to the L-DOPA 
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challenge of the 5,6-0HT treated mice was not statistically 
different from those of the controls whether in the case of 
the Everett test or the locomotor activity test; this sug-
gested a lack of pre.junctional type of dopamine receptor 
supersensitivity in 5,6-0HT treated mice. Longo et al. 
(1974) reported with the Everett test a transient increase 
in response to L-DOPA after 5,6-0HT. However, they did not 
evaluate their data statistically. 
Some dopaminergic supersensitivity of the postjunc-
tional type was evident in 5,6-0HT as well as 6-0HDA treated 
mice, because both groups exhibited enhanced responses to 
apomorphine. An enhanced response to apomorphine is gen-
erally interpreted as the phenomenon of postsynaptic DA 
receptor supersensitivity (Ungerstedt, 197la) • The response 
to apomorphine of 5,6-0HT treated mice was less than that 
of 6-0HDA treated mice. The enhanced response to apomor-
phine was of a transient nature in 5,6-0HT treated mice 
while it persisted in the 6-0HDA treated mice. It should be 
emphasized that the response to apomorphine, besides its 
well recognized effect on the DA receptor (Ernst, 1969) , may 
also depend in part on the state of the serotonergic neurons 
(Grabowska et al., 1974). Altogether, these data are con• 
sistent with the concept that the supersensitivity to L-DOPA 
and apomorphine is due to the nerve terminal lesion induced 
by 6-0HDA, as well as with the notion that the action of the 
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latter, just as that of 5,6-0HT is only relatively specific. 
The interaction of central noradrenergic and dopamin-
ergic receptors proposed by some investigators {Nyback et 
al., 1970; Consolo et al., 1975; Anden and Strombom, 1974) 
may have relevance to the lack of an enhanced response of 
5,6-0HT treated mice to L-DOPA. For example, Stromberg and 
Svensson {1971) suggested that the L-DOPA induced hyper-
activity in mice required both DA and NE receptor stimula-
tion. The lack of a marked supersensitivity of 5,6-0HT 
treated mice to L-DOPA may suggest that the postulated nor-
adrenergic-dopaminergic interaction was not altered in the 
same way by 5,6-0HT and 6-0HDA. 
SEVERAL COMMENTS ON THE NATURE OF CNS SUPERSENSITIVITY 
One might conclude that a decentralization type {cf. 
Introduction) of supersensitivity developed in the CNS fol-
lowing both 5,6-0HT and 6-0HDA. The decentralization con-
cept was implied by the results concerned with the choliner-
gic system. 6-0HDA and 5,6-0HT did not reduce brain ACh 
levels, suggesting that neither agent destroyed cholinergic 
neurons. However, both agents induced a supersensitivity to 
the cholinomimetic, tremorine. Thus, one might conclude 
that the cells containing the catecholamine and serotonin 
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receptors became supersensitive to the muscarinic agent, and 
that the supersensitivity induced, was similar to the non-
specific decentralization type of supersensitivity that oc-
curs in the periphery. Furthermore, as 6-0HDA induced a 
supersensitivity to L-5-HTP and as 5,6-0HT induced a super-
sensitivity to apomorphine these findings also suggested 
that a non-specific decentralization type of postsynaptic 
supersensitivity developed. Moreover, a 6-0HDA induced 
decentralization type of supersensitivity of DA receptors 
was suggested by others (Costall and Naylor, 1976). How-
ever, the results of Costall and Naylor (1976) are diffi-
cult to interpret as they could not demonstrate a supersen-
sitivity to dopamine in the same preparations that exhibited 
the "non-specific supersensitivity" to NE and 5-HT. This 
discrepancy casts doubt as to the utility of the method 
which they employed to demonstrate non-specific supersensi-
tivity. 
In contrast, careful review of our data suggests an 
alternative hypothesis to the concept of a decentralization 
type of CNS receptor supersensitivity. The data suggest the 
existence of the phenomena of specific postsynaptic receptor 
supersensitivity in the CNS. 6-0HDA induced a prolonged 
depletion of brain 5-HT; this suggests that 6-0HDA induced a 
lesion of 5-HT neurons. Thus the fact that 6-0HDA treatment 
induced a supersensitivity to L-5-HTP is consistent with the 
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concept of a specific 5-HT receptor supersensitivity that is 
secondary to a lesion of serotonergic neurons. Similarly, 
the fact that 5,6-0HT treatment induced a supersensitivity 
to apomorphine is consistent with the development of speci-
fic DA receptor supersensitivity that is secondary to a le-
sion of DA neurons~indeed, a 5,6-0HT induced lesion of dopa-
minergic neurons is suggested by the depletion of brain DA 
induced by this agent. Furthermore, the fact that after 
5,6-0HT, both the depletion of brain DA and the supersensi-
tivity to apomorphine were reversible suggested that these 
two phenomena were related. Furthermore, both the 5,6-0HT 
induced depletion of 5-HT as well as the supersensitivity to 
L-5-HTP were long lasting and these findings suggest that 
these phenomena were related. Lastly, both the 6-0HDA in-
duced depletion of DA as well as the supersensitivity to 
apomorphine were long lasting and these findings suggest 
that both of these phenomena were related. All these data 
emphasize the important concept that supersensitivity 
phenomena are correlated closely in time with neuronal de-
struction (i.e. neurotransmitter depletion). 
When receptors are in a state of decentralization 
supersensitivity, they simultaneously exhibit supersensitive 
responses to a variety of agonists (Sharpless, 1975). Thus, 
if 6-0HDA induced a state of decentralization supersensi-
tivity of either DA or 5-HT receptors these receptors would 
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exhibit simultaneous supersensitive responses to apomorphine, 
L-5-HTP and to tremorine. However, the 6-0HDA treated mice 
exhibited supersensitive responses to dopamimetics and L-5-
HTP for up to 20 days but to tremorine only up to the 4th 
day after treatment. Thus, a primary characteristic of non-
specific decentralization supersensitivity has not been ful-
filled, as the mice were not simultaneously supersensitive to 
apomorphine and tremorine or L-5-HTP on all of the days 
tested. Altogether, it appears that the 6-0HDA induced 
short term alteration of the cholinergic system can not be 
correlated with a lesion of cholinergic neurons (i.e. no ACh 
depletion) nor with a long term induction of supersensi-
tivity of DA and 5-HT receptors. Thus, the data suggest that 
the supersensitivity to tremorine may be related to other 
phenomena. 
Altogether, the data support a concept of specific 
rather than non-specific postsynaptic receptor supersensi-
tivity in the CNS. Thus, other mechanisms must be postulat-
ed to account for the enhanced response to tremorine. For 
example, if tremorine's action is dependent in part upon ACh 
release as suggested by Pepeu et al. (1974b), a 6-0HDA induced 
loss of striatal acetylcholinesterase activity may result in 
an apparent supersensitivity to tremorine. This latter con-
cept as well as the alternative hypotheses of neurotoxin in-
duced changes in cholinergic-dopaminergic or cholinergic-
serotonergic neuronal interactions (cf. previous 
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Discussion) may be involved in the tremorine response. 
Lastly, the induction of secondary compensatory changes 
within synaptic chains may also be a more likely explanation 
than to hypothesize the non-specific decentralization type 
of supersensitivity as an explanation for the tremorine re-
sponses. 
In summary, the data obtained suggest that a lesion of 
catecholamine neurons induced a supersensitivity to catecho-
laminergic agonists. Furthermore, a lesion of serotonergic 
neurons induced a supersensitive response to serotonergic 
agonists. Thus, a specific supersensitivity developed in 
the case of serotonergic and catecholaminergic neurons. The 
analogous case in the periphery is the prejunctional type of 
supersensitivity where the supersensitivity is specific in 
nature. In fact, the data suggest the development of both 
a prejunctional (L-DOPA) as well as a postjunctional (apo-
morphine) type of supersensitivity of dopaminergic recep-
tors. In the case of the 5-HTP response a prejunctional as 
well as postjunctional supersensitivity of serotonergic re-
ceptors could also have developed. Therefore, the data sug-
gest an important concept: the possibility that the post-
junctional form of supersensitivity of central catecholamine 
and serotonergic receptors is specific in nature, as opposed 
to non-specific in nature as it exists in the periphery. In 
fact, recent microiontophoretic studies also support the 
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concept of specific postsynaptic receptor supersensitivity 
in the CNS, as 6-0HDA treatment enhanced the response of 
striatal cells to DA but not to 5-HT or NE (Yarbrough and 
Phillis, 1975). Admittedly, a great deal of additional 
research would be required to resolve this complex and im-
portant issue. 
One may hypothesize that a specific postsynaptic 
supersensitive response may indicate that dopaminoceptive 
and serotonoceptive striatal cells receive only one physio-
logical transmitter input, dopamine or serotonin, respec-
tively. Thus, postsynaptic cells may develop a supersensi-
tive response to their physiological transmitter because 
they lack receptors for other neurotransmitters. This 
speculation,however, is not tenable in light of the demon-
stration of the receptiveness to both 5-HT and DA by stria• 
tal cells (Yarbrough and Phillis, 1975). 
Therefore, it is suggested that neurons of the CNS may 
develop a differential supersensitive response. Thus, when 
hypofunction occurs in only one neurotransmitter input, the 
postsynaptic neuron may respond by developing a postsynaptic 
supersensitive response to only that neurotransmitter which 
is deficient. Admittedly, such a corollary to Dale's prin-
ciple may be very speculative and much additional experimen-
tation would be required to substantiate such a phenomenon. 
However, the possibility of the presence of both a specific 
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postsynaptic as well as a specific prejunctional type of 
supersensitivity in the CNS represents a very elegant 
mechanism for maintenance of brain function within normal 
limits. 
Presynaptic as well as postsynaptic mechanisms of 
supersensitivity, as well as the recovery of functional 
pools may all be important in maintaining or restoring brain 
function. One can see from the results presented that even 
after "behavioral recovery" an abnormal state may still be 
present; such a state can be reflected by pharmacological 
hypofunction (subsensitivity) or hyperfunction (supersensi-
tivity). Thus, 6-0HDA decreased amphetamine's action as the 
latter depends on the presynaptic store of catecholamines. 
Similarly, 5,6-0HT induced a subsensitivity to the facilita-
tion by chlorimipramine of the hindlimb extensor reflex. 
which depends upon a presynaptic supply of 5-HT in the 
spinal cord (Daly et al., 1973). On the other hand, 6-0HDA 
and 5,6-0HT induce supersensitivity to apomorphine and L-5-
HTP respectively. Thus, a pharmacological presynaptic sub-
sensitivity may exist concomitantly with a postsynaptic 
pharmacologic supersensitivity while a minimal functional 
pool may be maintaining behavior within normal limits. 
The finding of supersensitivity in the catecholaminer-
gic systems is not a new concept, hut the employment of 
neurotoxins to induce this supersensitivity is n0vel. 
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Previously, supersensitivity has been demonstrated in the 
central catecholaminergic systems following: chronic reser-
pine treatment (Stolk and Rech, 1967; Rech and Stolk, 1970), 
axotomy (Trandelenburg, 1966) or the inhibition of catecho-
lamine synthesis (Dominic and Moore, 1969). Furthermore, 
recent research suggests that the sensitivity of catechola-
mine receptor may be altered by hormonal influences (Emlen 
et al., 1972; Engstrom et al., 1974; Huidobro-Toro et al., 
19 74) • 
The conclusion that the 5-HTP and L-DOPA supersensi-
tivity in the 5,6-0HT and 6-0HDA treated mice, respectively, 
is dependent upon the ultimate synthesis of the normal 
neurotransmitters, is evidenced by the fact that at effec-
tive doses, the decarboxylase inhibitor, RO 4-4602, com-
pletely blocked the 5-HTP as well as the L-DOPA response. 
It appears that the catecholamines and 5-HT rather than 
their precursors, are responsible for the responses to the 
L-DOPA and 5-HTP challenge, respectively, and that when the 
formation of the bioamines is prevented by the decarboxylase 
inhibitor (Pletscher and Bartholini, 1971; Hyttel et al., 
1972) the response to the precursor is blocked. Furthermore 
it is of interest that at low doses, RO 4-4602 potentiated 
the central while attenuating the peripheral actions of 5-
HTP. This is consistent with the fact that at these low 
doses RO 4-4602 blocks decarboxylase peripherally but not 
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centrally (Pletscher and Bartholini, 1971), thus increasing 
the availability of 5-HTP to the CNS. 
SUMMARY 
The results of this study indicate no specificity and 
a relative rather then an absolute selectivity for both 
agents. In the case of 6-0HDA a specific lesion of the 
catecholamine system was expected and the following findings 
supported such a contention: a) NE and DA were depleted for 
a long time period; b) the responses to L-DOPA or apomor-
phine were exaggerated over the same time period whether 
evaluated in terms of the locomotor activity, the Everett 
test or finally by observation; c) the response to ampheta-
mine was decreased throughout the study; d) the brain con-
tent of ACh was not affected. However, a case for non-
specificity of the action of 6-0HDA may also be made: a) 
brain 5-HT was depleted throughout the study; b) the re-
sponse to L-5-HTP was exaggerated throughout the study; 
c) transient changes in cholinergic function were observed 
as evidenced by an enhanced tremorigenic effect to 
tremorine on the fourth post-treatment day. 
Similarly, in the case of 5,6-0HT a specific lesion of 
the indolamine system was expected. The following experi-
mental results suggest that the expectation was realized: 
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a) long lasting depletion of brain 5-HT; b) long lasting 
exaggerated responses to L-5-HTP; c) a lack of effect on ACh 
content. However, a case for non-specificity of 5,6-0HT may 
also be made since transient decreases in brain NE and DA 
were observed up to the lOth post-treatment day and an en-
hanced response to apomorphine existed to the lOth post-
treatment day. Finally, the tremor response to tremorine 
was increased for some time implying either a serotonergic 
mechanism, a cholinergic-serotonergic interaction, or a bio-
chemically undetected change in the function of the choli-
nergic system was induced by 5,6-0HT treatment. 
The results of this study emphasize the multitrans-
mitter phenomena involved in the actions of 6-0HDA and 
5,6-0HT, as well as the concomitant complexities of their 
effects on drug responses and on behavioral paradigms. A 
relatively selective lesion of indolamine neurons may be an 
achievable goal with 5,6-0HT if sufficient time is allowed 
for the restoration of NE and DA levels following their 
initial depletion. However, without concomitant morphologi-
cal or kinetic studies such a selectivity may only be sug-
gested by the present data. Furthermore, it is interesting 
to note that although behavioral recovery may be manifested 
following these neurotoxic agents (i.e. normal locomotive 
behavior) , there may remain a "pharmacodynamic alteration" 
(i.e. hypersensitivity or subsensitivity). Such lasting 
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pharmacological alterations may be exploited by the 
judicious use of agonist agents such as apomorphine, L-5-
~TP and tremorine as neuropsychodiagnostic tools to help 
elucidate the nature of neuropathology whether in the case 
of emotive, cognitive or neurological involvements. Such 
an approach may be desirable to help identify the etiologies 
of dyfunctions which may result in common behavioral ex-
pressions such as the schizoid states, depressions and 
choreas. Obviously, different behavioral substrates may 
have different susceptibilities to both impairment and re-
covery and each needs to be evaluated individually in that 
regard. 
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